,coef,coef_graph,coef_combined,coef_combined_zscore,coef_combined2
5-Phosphoribose 1-diphosphate biosynthesis,3.8311248e-09,2.0,3.8311248e-09,-0.19435601,0.26040715
A tetrasaccharide linker sequence is required for GAG synthesis,3.2115473e-05,8.0,3.2115473e-05,-0.10048613,0.057479694
ABC transporters in lipid homeostasis,3.584439e-06,9.0,3.584439e-06,-0.18388905,-0.05113523
ADP signalling through P2Y purinoceptor 1,0.0005116923,14.0,0.0005116923,1.3014299,0.8422924
ADP signalling through P2Y purinoceptor 12,3.572144e-05,13.0,3.572144e-05,-0.08994504,-0.16273633
AKT phosphorylates targets in the cytosol,5.9515038e-05,13.0,5.9515038e-05,-0.020390755,-0.110214055
AKT phosphorylates targets in the nucleus,6.5729596e-06,8.0,6.5729596e-06,-0.17515291,0.001096849
AKT-mediated inactivation of FOXO1A,1.9930091e-08,4.0,1.9930091e-08,-0.19430897,0.16917229
ALKBH2 mediated reversal of alkylation damage,5.2253e-10,2.0,5.2253e-10,-0.1943657,0.26039982
ALKBH3 mediated reversal of alkylation damage,7.3385667e-07,3.0,7.3385667e-07,-0.192222,0.2163834
AMPK inhibits chREBP transcriptional activation activity,1.4278557e-07,6.0,1.4278557e-07,-0.19394983,0.07817313
APC truncation mutants are not K63 polyubiquitinated,0.0,1.0,0.0,-0.19436722,0.30603385
APC truncation mutants have impaired AXIN binding,1.0268714e-05,10.0,1.0268714e-05,-0.16434936,-0.08201547
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1,0.0001258929,42.0,0.0001258929,0.17364736,-1.2871108
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway,3.557646e-09,6.0,3.557646e-09,-0.19435681,0.077865794
APOBEC3G mediated resistance to HIV-1 infection,9.923946e-09,4.0,9.923946e-09,-0.1943382,0.1691502
ARL13B-mediated ciliary trafficking of INPP5E,1.2337854e-08,3.0,1.2337854e-08,-0.19433115,0.21479072
ATF4 activates genes,2.739726e-10,2.0,2.739726e-10,-0.19436641,0.26039928
ATF6 (ATF6-alpha) activates chaperone genes,1.5364161e-07,6.0,1.5364161e-07,-0.1939181,0.07819709
ATP sensitive Potassium channels,4.0984173e-07,2.0,4.0984173e-07,-0.19316916,0.26130337
AUF1 (hnRNP D0) binds and destabilizes mRNA,1.9244833e-05,32.0,1.9244833e-05,-0.13811004,-1.0661752
AURKA Activation by TPX2,0.0008921761,48.0,0.0008921761,2.4136736,0.13058111
AXIN missense mutants destabilize the destruction complex,4.1788477e-05,10.0,4.1788477e-05,-0.07220966,-0.012438352
Abacavir metabolism,2.7235803e-06,3.0,2.7235803e-06,-0.18640555,0.22077557
Abacavir transmembrane transport,0.0,1.0,0.0,-0.19436722,0.30603385
Abasic sugar-phosphate removal via the single-nucleotide replacement pathway,3.3741724e-06,2.0,3.3741724e-06,-0.18450372,0.26784688
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,6.0868825e-07,2.0,6.0868825e-07,-0.1925879,0.2617423
Acetylation,0.0,1.0,0.0,-0.19436722,0.30603385
Acetylcholine Neurotransmitter Release Cycle,2.739748e-05,6.0,2.739748e-05,-0.11427794,0.13833548
Acetylcholine regulates insulin secretion,3.7424325e-06,6.0,3.7424325e-06,-0.18342721,0.08611904
Acrosome Reaction,0.0,1.0,0.0,-0.19436722,0.30603385
Activated NOTCH1 Transmits Signal to the Nucleus,4.3835183e-08,20.0,4.3835183e-08,-0.19423907,-0.5609377
Activated NTRK2 signals through CDK5,0.00085044396,5.0,0.00085044396,2.2916808,2.0007734
Activated NTRK2 signals through FRS2 and FRS3,2.062154e-05,7.0,2.062154e-05,-0.1340856,0.07774302
Activated NTRK2 signals through FYN,0.00020911157,5.0,0.00020911157,0.41691518,0.58508855
Activated NTRK2 signals through PI3K,1.8096124e-06,4.0,1.8096124e-06,-0.1890773,0.17312285
Activated NTRK2 signals through PLCG1,1.4090589e-05,2.0,1.4090589e-05,-0.15317711,0.29150245
Activated NTRK2 signals through RAS,0.000107476044,5.0,0.000107476044,0.11981056,0.3607371
Activated NTRK3 signals through PI3K,0.0001914864,5.0,0.0001914864,0.36539257,0.5461825
Activated NTRK3 signals through PLCG1,0.0020300867,2.0,0.0020300867,5.740054,4.7416368
Activated NTRK3 signals through RAS,0.00012540635,5.0,0.00012540635,0.17222507,0.40031663
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,9.462624e-05,11.0,9.462624e-05,0.08224755,0.058561184
Activation and oligomerization of BAK protein,0.00027749635,3.0,0.00027749635,0.61682,0.8273123
Activation of AMPA receptors,0.0,1.0,0.0,-0.19436722,0.30603385
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins,0.0001116036,43.0,0.0001116036,0.13187638,-1.3642883
Activation of ATR in response to replication stress,7.0396054e-05,22.0,7.0396054e-05,0.011417018,-0.49691173
Activation of BAD and translocation to mitochondria ,1.0484281e-08,10.0,1.0484281e-08,-0.19433658,-0.104659595
Activation of BIM and translocation to mitochondria ,1.765518e-05,3.0,1.765518e-05,-0.14275697,0.25373575
Activation of BMF and translocation to mitochondria,3.822521e-07,4.0,3.822521e-07,-0.19324982,0.16997208
Activation of C3 and C5,0.0,1.0,0.0,-0.19436722,0.30603385
Activation of DNA fragmentation factor,1.9161688e-07,8.0,1.9161688e-07,-0.19380707,-0.0129894065
Activation of G protein gated Potassium channels,5.7049867e-05,10.0,5.7049867e-05,-0.027597029,0.021249823
Activation of Matrix Metalloproteinases,9.612081e-09,6.0,9.612081e-09,-0.19433913,0.07787917
Activation of NF-kappaB in B cells,1.2350058e-07,46.0,1.2350058e-07,-0.19400619,-1.7472764
Activation of NOXA and translocation to mitochondria,3.3584056e-05,4.0,3.3584056e-05,-0.09619312,0.24326216
Activation of Nicotinic Acetylcholine Receptors,2.5555114e-10,4.0,2.5555114e-10,-0.19436647,0.16912887
Activation of PPARGC1A (PGC-1alpha) by phosphorylation,2.0001703e-06,6.0,2.0001703e-06,-0.18852025,0.08227314
Activation of PUMA and translocation to mitochondria,3.1734005e-06,6.0,3.1734005e-06,-0.18509062,0.084862955
Activation of RAC1,1.0022102e-07,5.0,1.0022102e-07,-0.19407426,0.12371436
Activation of RAS in B cells,2.8858935e-08,5.0,2.8858935e-08,-0.19428286,0.12355682
Activation of SMO,4.4128768e-07,4.0,4.4128768e-07,-0.19307724,0.17010239
Activation of TRKA receptors,5.602566e-05,2.0,5.602566e-05,-0.030591028,0.38407037
Activation of anterior HOX genes in hindbrain development during early embryogenesis,2.4776243e-08,44.0,2.4776243e-08,-0.1942948,-1.6562239
Activation of gene expression by SREBF (SREBP),0.00024800887,17.0,0.00024800887,0.5306211,0.12332881
Activation of the TFAP2 (AP-2) family of transcription factors,1.0976078e-07,4.0,1.0976078e-07,-0.19404638,0.16937058
"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S",9.304654e-06,31.0,9.304654e-06,-0.16716753,-1.0424821
Activation of the pre-replicative complex,3.7075395e-05,22.0,3.7075395e-05,-0.08598711,-0.57046413
"Activation, myristolyation of BID and translocation to mitochondria",1.7075952e-05,4.0,1.7075952e-05,-0.14445019,0.20682198
"Activation, translocation and oligomerization of BAX",5.4425514e-06,3.0,5.4425514e-06,-0.17845735,0.22677745
Acyl chain remodeling of CL,6.458636e-07,6.0,6.458636e-07,-0.19247921,0.07928363
Acyl chain remodeling of DAG and TAG,4.8195176e-07,4.0,4.8195176e-07,-0.19295835,0.17019215
Acyl chain remodelling of PC,6.045672e-07,9.0,6.045672e-07,-0.19259992,-0.05771304
Acyl chain remodelling of PE,8.5188856e-07,8.0,8.5188856e-07,-0.19187695,-0.011531913
Acyl chain remodelling of PG,4.8514715e-07,4.0,4.8514715e-07,-0.19294903,0.17019922
Acyl chain remodelling of PI,2.1604224e-06,4.0,2.1604224e-06,-0.1880518,0.17389724
Acyl chain remodelling of PS,9.574476e-08,4.0,9.574476e-08,-0.19408734,0.16933964
Adrenaline signalling through Alpha-2 adrenergic receptor,2.1142847e-09,2.0,2.1142847e-09,-0.19436103,0.26040334
"Adrenaline,noradrenaline inhibits insulin secretion",0.00010741087,14.0,0.00010741087,0.11962005,-0.05012337
Advanced glycosylation endproduct receptor signaling,2.6552573e-06,10.0,2.6552573e-06,-0.18660527,-0.0988215
Aflatoxin activation and detoxification,2.1825772e-05,6.0,2.1825772e-05,-0.13056536,0.1260364
Agmatine biosynthesis,0.0,1.0,0.0,-0.19436722,0.30603385
Alpha-defensins,1.5081482e-09,2.0,1.5081482e-09,-0.19436282,0.260402
Alpha-oxidation of phytanate,3.0081167e-06,6.0,3.0081167e-06,-0.1855738,0.08449809
Alternative complement activation,1.1670496e-08,2.0,1.1670496e-08,-0.1943331,0.26042444
Amine ligand-binding receptors,1.3427382e-07,5.0,1.3427382e-07,-0.19397472,0.12378952
Amino acid transport across the plasma membrane,1.8487232e-05,11.0,1.8487232e-05,-0.14032468,-0.10950897
Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal,1.3095776e-06,52.0,1.3095776e-06,-0.19053902,-2.018469
Amyloid fiber formation,4.2709486e-05,28.0,4.2709486e-05,-0.06951734,-0.8318384
Anchoring fibril formation,0.0,1.0,0.0,-0.19436722,0.30603385
Anchoring of the basal body to the plasma membrane,4.082024e-06,63.0,4.082024e-06,-0.1824345,-2.5143363
Androgen biosynthesis,1.0321783e-07,2.0,1.0321783e-07,-0.1940655,0.26062652
Antagonism of Activin by Follistatin,1.9478248e-09,3.0,1.9478248e-09,-0.19436152,0.2147678
"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",3.629755e-06,18.0,3.629755e-06,-0.18375659,-0.4617518
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,1.07056486e-07,21.0,1.07056486e-07,-0.19405426,-0.60643333
Antigen processing: Ubiquitination & Proteasome degradation,1.4132441e-06,179.0,7.895219e-09,-0.19434415,-7.8139076
Apoptotic cleavage of cell adhesion  proteins,4.6752868e-07,4.0,4.6752868e-07,-0.19300051,0.17016032
Arachidonate production from DAG,2.6578743e-07,4.0,2.6578743e-07,-0.19359025,0.169715
Aryl hydrocarbon receptor signalling,9.099227e-06,6.0,9.099227e-06,-0.16776805,0.09794369
Assembly of active LPL and LIPC lipase complexes,4.2694694e-05,8.0,4.2694694e-05,-0.06956058,0.08083239
Assembly of the ORC complex at the origin of replication,2.3195043e-06,6.0,2.3195043e-06,-0.18758677,0.08297805
Association of TriC/CCT with target proteins during biosynthesis,4.5603295e-07,28.0,4.5603295e-07,-0.19303413,-0.9251092
Astrocytic Glutamate-Glutamine Uptake And Metabolism,5.053758e-07,4.0,5.053758e-07,-0.1928899,0.17024386
Asymmetric localization of PCP proteins,0.0004272699,39.0,0.0004272699,1.0546433,-0.48494202
Attachment of GPI anchor to uPAR,1.8723314e-07,5.0,1.8723314e-07,-0.1938199,0.12390643
Attenuation phase,5.4531615e-06,12.0,5.4531615e-06,-0.17842634,-0.18391572
Autodegradation of Cdh1 by Cdh1:APC/C,0.00064551306,41.0,0.00064551306,1.6926194,-0.094459735
Axonal growth inhibition (RHOA activation),1.7952508e-06,5.0,1.7952508e-06,-0.1891193,0.12745598
Axonal growth stimulation,3.311308e-06,4.0,3.311308e-06,-0.18468748,0.17643772
B-WICH complex positively regulates rRNA expression,5.465623e-07,25.0,5.465623e-07,-0.19276948,-0.78800386
BBSome-mediated cargo-targeting to cilium,9.740583e-07,8.0,9.740583e-07,-0.19151981,-0.011262231
BDNF activates NTRK2 (TRKB) signaling,0.0,1.0,0.0,-0.19436722,0.30603385
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,3.052761e-07,5.0,3.052761e-07,-0.19347483,0.12416701
"BMAL1:CLOCK,NPAS2 activates circadian gene expression",1.1279285e-05,5.0,1.1279285e-05,-0.16139522,0.14839116
Basigin interactions,3.45182e-05,9.0,3.45182e-05,-0.09346239,0.017148325
Beta defensins,3.7862293e-08,5.0,3.7862293e-08,-0.19425653,0.12357671
Beta-catenin phosphorylation cascade,1.5788202e-05,11.0,1.5788202e-05,-0.1482146,-0.11546685
Beta-oxidation of pristanoyl-CoA,1.2732514e-06,5.0,1.2732514e-06,-0.19064522,0.12630372
Beta-oxidation of very long chain fatty acids,3.1985895e-05,8.0,3.1985895e-05,-0.10086492,0.057193663
Bicarbonate transporters,3.903717e-08,3.0,3.903717e-08,-0.19425312,0.21484967
Binding of TCF/LEF:CTNNB1 to target gene promoters,3.5220512e-07,7.0,3.5220512e-07,-0.19333763,0.03300025
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB,0.0,1.0,0.0,-0.19436722,0.30603385
"Biosynthesis of A2E, implicated in retinal degradation",1.0818183e-10,2.0,1.0818183e-10,-0.1943669,0.26039892
Biosynthesis of D-series resolvins,4.184291e-05,4.0,4.184291e-05,-0.07205054,0.26149285
Biosynthesis of DHA-derived sulfido conjugates,0.0,1.0,0.0,-0.19436722,0.30603385
Biosynthesis of DPAn-3 SPMs,3.2300291e-09,3.0,3.2300291e-09,-0.19435778,0.21477063
Biosynthesis of DPAn-6 SPMs,2.6923557e-09,2.0,2.6923557e-09,-0.19435935,0.26040462
Biosynthesis of E-series 18(R)-resolvins,0.00016481211,4.0,0.00016481211,0.28741738,0.5329366
Biosynthesis of E-series 18(S)-resolvins,9.553857e-05,4.0,9.553857e-05,0.08491451,0.38002127
Biosynthesis of aspirin-triggered D-series resolvins,1.008531e-05,4.0,1.008531e-05,-0.16488549,0.19139074
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives,1.4937175e-08,2.0,1.4937175e-08,-0.19432355,0.26043165
Biosynthesis of maresins,4.914021e-07,2.0,4.914021e-07,-0.19293073,0.2614834
Biosynthesis of protectins,4.675785e-09,2.0,4.675785e-09,-0.19435355,0.260409
Biotin transport and metabolism,3.573492e-05,11.0,3.573492e-05,-0.089905635,-0.07143623
Breakdown of the nuclear lamina,3.4720188e-08,3.0,3.4720188e-08,-0.19426572,0.21484013
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,6.707479e-07,13.0,6.707479e-07,-0.19240646,-0.24010764
Butyrophilin (BTN) family interactions,4.0908173e-08,7.0,4.0908173e-08,-0.19424765,0.032313082
C6 deamination of adenosine,6.0599637e-13,2.0,6.0599637e-13,-0.19436722,0.2603987
CASP8 activity is inhibited,5.0831545e-06,9.0,5.0831545e-06,-0.17950797,-0.047826964
CD209 (DC-SIGN) signaling,3.5290157e-08,15.0,3.5290157e-08,-0.19426407,-0.3327807
CD22 mediated BCR regulation,1.0549021e-05,5.0,1.0549021e-05,-0.16352995,0.14677916
CD28 dependent PI3K/Akt signaling,7.670338e-09,13.0,7.670338e-09,-0.1943448,-0.24157132
CD28 dependent Vav1 pathway,2.823415e-08,9.0,2.823415e-08,-0.19428469,-0.058985256
CDC6 association with the ORC:origin complex,2.551979e-07,7.0,2.551979e-07,-0.19362122,0.032786105
CDK-mediated phosphorylation and removal of Cdc6,6.072306e-07,44.0,6.072306e-07,-0.19259214,-1.6549382
CDO in myogenesis,1.5308509e-06,18.0,1.5308509e-06,-0.18989217,-0.4663849
CDT1 association with the CDC6:ORC:origin complex,9.180445e-06,36.0,9.180445e-06,-0.16753061,-1.2709322
CHL1 interactions,1.9102977e-07,4.0,1.9102977e-07,-0.1938088,0.16954997
CLEC7A (Dectin-1) induces NFAT activation,2.4998621e-06,7.0,2.4998621e-06,-0.18705954,0.037741
CLEC7A/inflammasome pathway,3.633637e-08,3.0,3.633637e-08,-0.194261,0.2148437
COPI-dependent Golgi-to-ER retrograde traffic,2.6375095e-05,41.0,2.6375095e-05,-0.11726661,-1.4611524
COPI-independent Golgi-to-ER retrograde traffic,2.0295349e-05,25.0,2.0295349e-05,-0.13503914,-0.7444101
COPI-mediated anterograde transport,0.00047809765,59.0,0.00047809765,1.2032248,-1.2854477
COPII-mediated vesicle transport,0.0006215617,51.0,0.0006215617,1.622604,-0.60368204
COX reactions,1.6161732e-07,2.0,1.6161732e-07,-0.19389476,0.26075545
CREB3 factors activate genes,2.8389135e-07,5.0,2.8389135e-07,-0.19353734,0.1241198
CRMPs in Sema3A signaling,2.5211402e-10,7.0,2.5211402e-10,-0.19436647,0.032223348
CS/DS degradation,1.5380774e-06,7.0,1.5380774e-06,-0.18987106,0.035617955
CTLA4 inhibitory signaling,6.6317665e-07,15.0,6.6317665e-07,-0.1924286,-0.3313947
Ca2+ activated K+ channels,4.52287e-07,3.0,4.52287e-07,-0.19304508,0.21576187
Ca2+ pathway,0.00057864084,35.0,0.00057864084,1.4971362,0.0317368
Calcineurin activates NFAT,7.7516177e-10,7.0,7.7516177e-10,-0.19436495,0.032224502
Calcitonin-like ligand receptors,0.0,1.0,0.0,-0.19436722,0.30603385
Calmodulin induced events,3.647814e-07,9.0,3.647814e-07,-0.19330089,-0.058242347
Calnexin/calreticulin cycle,1.0905446e-07,19.0,1.0905446e-07,-0.19404843,-0.51515853
Carboxyterminal post-translational modifications of tubulin,2.8905272e-06,13.0,2.8905272e-06,-0.18591753,-0.23520768
Cargo concentration in the ER,5.542236e-06,19.0,5.542236e-06,-0.17816596,-0.5031653
Cargo recognition for clathrin-mediated endocytosis,2.8052496e-06,60.0,2.8052496e-06,-0.18616681,-2.3802493
Carnitine synthesis,2.047098e-09,4.0,2.047098e-09,-0.19436124,0.16913281
Caspase-mediated cleavage of cytoskeletal proteins,3.1668867e-06,11.0,3.1668867e-06,-0.18510966,-0.14332728
Catecholamine biosynthesis,0.0,1.0,0.0,-0.19436722,0.30603385
Cation-coupled Chloride cotransporters,8.7088736e-08,3.0,8.7088736e-08,-0.19411264,0.21495573
Cell redox homeostasis,0.0,1.0,0.0,-0.19436722,0.30603385
Cellular hexose transport,1.2801151e-05,8.0,1.2801151e-05,-0.15694644,0.014845036
Centrosome maturation,5.8815407e-05,54.0,5.8815407e-05,-0.022435939,-1.9828005
Ceramide signalling,1.0821657e-09,2.0,1.0821657e-09,-0.19436406,0.2604011
ChREBP activates metabolic gene expression,3.1212044e-06,5.0,3.1212044e-06,-0.1852432,0.13038291
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,2.9883708e-07,6.0,2.9883708e-07,-0.19349365,0.07851761
Cholesterol biosynthesis via desmosterol,2.619121e-05,2.0,2.619121e-05,-0.11780415,0.31821346
Cholesterol biosynthesis via lathosterol,7.53704e-06,2.0,7.53704e-06,-0.17233467,0.27703604
Choline catabolism,1.9036264e-08,2.0,1.9036264e-08,-0.19431157,0.2604407
Chondroitin sulfate biosynthesis,2.1592275e-06,11.0,2.1592275e-06,-0.18805529,-0.1455516
Chylomicron assembly,3.6433153e-08,2.0,3.6433153e-08,-0.19426073,0.2604791
Chylomicron clearance,7.435435e-07,2.0,7.435435e-07,-0.19219366,0.26204
Chylomicron remodeling,5.243796e-07,3.0,5.243796e-07,-0.19283433,0.21592103
Citric acid cycle (TCA cycle),1.0524815e-05,19.0,1.0524815e-05,-0.16360071,-0.49216673
Class C/3 (Metabotropic glutamate/pheromone receptors),3.4857825e-10,4.0,3.4857825e-10,-0.1943662,0.16912906
Classical Kir channels,4.8364166e-07,2.0,4.8364166e-07,-0.19295342,0.2614663
Cleavage of Growing Transcript in the Termination Region ,9.974189e-07,50.0,9.974189e-07,-0.19145153,-1.927888
Cleavage of the damaged purine,2.6225002e-13,2.0,2.6225002e-13,-0.19436722,0.2603987
Cleavage of the damaged pyrimidine ,1.1268542e-11,8.0,1.1268542e-11,-0.19436717,-0.013412355
"Cobalamin (Cbl, vitamin B12) transport and metabolism",4.6518813e-05,9.0,4.6518813e-05,-0.058381777,0.04363862
Coenzyme A biosynthesis,2.6221999e-08,4.0,2.6221999e-08,-0.19429056,0.16918617
Cohesin Loading onto Chromatin,5.4570903e-09,8.0,5.4570903e-09,-0.19435127,-0.013400342
Collagen chain trimerization,2.4852028e-07,9.0,2.4852028e-07,-0.19364074,-0.058498986
Collagen degradation,3.5522025e-06,11.0,3.5522025e-06,-0.1839833,-0.14247674
Common Pathway of Fibrin Clot Formation,7.973076e-06,5.0,7.973076e-06,-0.17106004,0.14109299
Complex I biogenesis,8.286598e-05,24.0,8.286598e-05,0.047869556,-0.56065583
Condensation of Prometaphase Chromosomes,3.7237055e-07,5.0,3.7237055e-07,-0.1932787,0.124315105
Condensation of Prophase Chromosomes,4.2904936e-05,13.0,4.2904936e-05,-0.06894599,-0.14687939
Conjugation of carboxylic acids,1.340121e-06,2.0,1.340121e-06,-0.19044973,0.2633569
Constitutive Signaling by AKT1 E17K in Cancer,1.4240717e-05,21.0,1.4240717e-05,-0.15273826,-0.57523453
Constitutive Signaling by Aberrant PI3K in Cancer,1.1807037e-08,31.0,1.1807037e-08,-0.1943327,-1.0629954
Constitutive Signaling by EGFRvIII,4.1676427e-05,13.0,4.1676427e-05,-0.07253721,-0.14959122
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,9.867397e-06,16.0,9.867397e-06,-0.16552249,-0.35671237
Constitutive Signaling by NOTCH1 HD Domain Mutants,0.00016602289,11.0,0.00016602289,0.29095677,0.21616304
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1.9951389e-05,40.0,1.9951389e-05,-0.1360446,-1.429697
Constitutive Signaling by NOTCH1 PEST Domain Mutants,1.6140445e-06,40.0,1.6140445e-06,-0.18964899,-1.470175
Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,0.0001184077,5.0,0.0001184077,0.15176636,0.38486773
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase,0.00018055523,13.0,0.00018055523,0.33343822,0.15697154
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,2.0385194e-07,21.0,2.0385194e-07,-0.19377132,-0.60621965
Creatine metabolism,0.00025921705,5.0,0.00025921705,0.56338525,0.695692
Creation of C4 and C2 activators,2.2265269e-08,2.0,2.2265269e-08,-0.19430214,0.26044783
Cristae formation,7.913618e-09,8.0,7.913618e-09,-0.19434407,-0.013394913
Cross-presentation of particulate exogenous antigens (phagosomes),6.4483856e-07,4.0,6.4483856e-07,-0.1924822,0.17055172
Cross-presentation of soluble exogenous antigens (endosomes),3.2062122e-08,28.0,3.2062122e-08,-0.19427349,-0.92604506
Crosslinking of collagen fibrils,6.7540334e-10,2.0,6.7540334e-10,-0.19436525,0.26040018
Cyclin A/B1/B2 associated events during G2/M transition,1.9243917e-06,11.0,1.9243917e-06,-0.18874177,-0.14606999
Cyclin D associated events in G1,0.0016237629,32.0,0.0016237629,4.5522738,2.4756575
Cysteine formation from homocysteine,4.0672825e-07,3.0,4.0672825e-07,-0.19317827,0.21566132
Cytochrome c-mediated apoptotic response,3.3619247e-07,6.0,3.3619247e-07,-0.19338445,0.078600064
Cytosolic iron-sulfur cluster assembly,3.8671683e-08,8.0,3.8671683e-08,-0.19425417,-0.013327023
Cytosolic tRNA aminoacylation,0.0003069429,18.0,0.0003069429,0.70289916,0.20778535
DAP12 signaling,3.3538605e-08,21.0,3.3538605e-08,-0.19426917,-0.60659564
DCC mediated attractive signaling,1.0233333e-07,9.0,1.0233333e-07,-0.19406807,-0.058821674
DEx/H-box helicases activate type I IFN and inflammatory cytokines production ,4.290084e-08,7.0,4.290084e-08,-0.19424182,0.032317482
DNA Damage Recognition in GG-NER,2.3181335e-07,21.0,2.3181335e-07,-0.19368958,-0.6061579
DNA methylation,1.1691965e-05,9.0,1.1691965e-05,-0.16018885,-0.033238582
DNA replication initiation,2.7636693e-08,6.0,2.7636693e-08,-0.19428644,0.07791895
DSCAM interactions,2.3269006e-10,7.0,2.3269006e-10,-0.19436654,0.03222329
Deactivation of the beta-catenin transactivating complex,0.001447118,25.0,0.001447118,4.035899,2.4051752
Deadenylation of mRNA,2.5225896e-05,16.0,2.5225896e-05,-0.12062598,-0.32280982
Dectin-1 mediated noncanonical NF-kB signaling,2.566909e-06,36.0,2.566909e-06,-0.18686354,-1.285531
Dectin-2 family,2.6296914e-07,8.0,2.6296914e-07,-0.19359851,-0.012831909
Defective ABCA1 causes Tangier disease,0.0,1.0,0.0,-0.19436722,0.30603385
Defective ABCA12 causes autosomal recessive congenital ichthyosis type 4B,0.0,1.0,0.0,-0.19436722,0.30603385
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction 3 (SMDP3),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ABCB11 causes progressive familial intrahepatic cholestasis 2 and benign recurrent intrahepatic cholestasis 2,0.0,1.0,0.0,-0.19436722,0.30603385
"Defective ABCB4 causes progressive familial intrahepatic cholestasis 3, intrahepatic cholestasis of pregnancy 3 and gallbladder disease 1",0.0,1.0,0.0,-0.19436722,0.30603385
Defective ABCB6 causes isolated colobomatous microphthalmia 7 (MCOPCB7),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ABCC2 causes Dubin-Johnson syndrome,0.0,1.0,0.0,-0.19436722,0.30603385
Defective ABCC6 causes pseudoxanthoma elasticum (PXE),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ABCC8 can cause hypoglycemias and hyperglycemias,0.0,1.0,0.0,-0.19436722,0.30603385
"Defective ABCC9 causes dilated cardiomyopathy 10, familial atrial fibrillation 12 and hypertrichotic osteochondrodysplasia",0.0,1.0,0.0,-0.19436722,0.30603385
Defective ABCD1 causes adrenoleukodystrophy (ALD),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective ABCD4 causes methylmalonic aciduria and homocystinuria, cblj type (MAHCJ)",0.0,2.0,0.0,-0.19436722,0.2603987
Defective ABCG5 causes sitosterolemia,0.0,1.0,0.0,-0.19436722,0.30603385
Defective ABCG8 causes gallbladder disease 4 and sitosterolemia,0.0,1.0,0.0,-0.19436722,0.30603385
Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD),3.2773846e-06,2.0,3.2773846e-06,-0.18478666,0.2676332
Defective ACY1 causes encephalopathy,0.0,1.0,0.0,-0.19436722,0.30603385
Defective AHCY causes Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ALG1 causes ALG1-CDG (CDG-1k),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ALG11 causes ALG11-CDG (CDG-1p),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ALG12 causes ALG12-CDG (CDG-1g),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ALG2 causes ALG2-CDG (CDG-1i),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ALG3 causes ALG3-CDG (CDG-1d),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ALG6 causes ALG6-CDG (CDG-1c),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ALG8 causes ALG8-CDG (CDG-1h),0.0,1.0,0.0,-0.19436722,0.30603385
Defective ALG9 causes ALG9-CDG (CDG-1l),0.0,1.0,0.0,-0.19436722,0.30603385
Defective AMN causes hereditary megaloblastic anemia 1,0.0,1.0,0.0,-0.19436722,0.30603385
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),5.3450565e-13,2.0,5.3450565e-13,-0.19436722,0.2603987
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),5.3450565e-13,2.0,5.3450565e-13,-0.19436722,0.2603987
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),5.959282e-07,2.0,5.959282e-07,-0.19262518,0.26171413
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),5.959282e-07,2.0,5.959282e-07,-0.19262518,0.26171413
Defective B3GALT6 causes EDSP2 and SEMDJL1,3.0816825e-06,4.0,3.0816825e-06,-0.18535875,0.17593083
Defective B3GALTL causes Peters-plus syndrome (PpS),8.884476e-14,2.0,8.884476e-14,-0.19436722,0.2603987
Defective B3GAT3 causes JDSSDHD,3.7364116e-06,4.0,3.7364116e-06,-0.1834448,0.17737609
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.19436722,0.30603385
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.19436722,0.30603385
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.19436722,0.30603385
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective B4GALT7 causes EDS, progeroid type",1.5716318e-05,4.0,1.5716318e-05,-0.14842473,0.2038207
Defective BTD causes biotidinase deficiency,0.0,1.0,0.0,-0.19436722,0.30603385
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),1.1544949e-08,3.0,1.1544949e-08,-0.19433346,0.21478897
Defective CD320 causes methylmalonic aciduria,9.09526e-10,3.0,9.09526e-10,-0.19436456,0.21476552
Defective CFTR causes cystic fibrosis,5.677056e-05,38.0,5.677056e-05,-0.028413504,-1.2571516
"Defective CHST14 causes EDS, musculocontractural type",1.9992736e-07,2.0,1.9992736e-07,-0.19378278,0.26084
Defective CHST3 causes SEDCJD,1.4814353e-07,2.0,1.4814353e-07,-0.19393416,0.2607257
Defective CHST6 causes MCDC1,0.0,1.0,0.0,-0.19436722,0.30603385
Defective CHSY1 causes TPBS,3.265405e-05,2.0,3.265405e-05,-0.09891175,0.33247963
Defective CP causes aceruloplasminemia (ACERULOP),0.0,1.0,0.0,-0.19436722,0.30603385
Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4),1.6813557e-08,2.0,1.6813557e-08,-0.19431807,0.2604358
Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5),1.3230859e-07,2.0,1.3230859e-07,-0.19398046,0.26069075
Defective CUBN causes hereditary megaloblastic anemia 1,0.0,1.0,0.0,-0.19436722,0.30603385
"Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)",7.3078894e-07,3.0,7.3078894e-07,-0.19223095,0.21637663
Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4),0.0,1.0,0.0,-0.19436722,0.30603385
Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency),0.0,1.0,0.0,-0.19436722,0.30603385
Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5),0.0,1.0,0.0,-0.19436722,0.30603385
Defective CYP19A1 causes Aromatase excess syndrome (AEXS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective CYP1B1 causes Glaucoma,0.0,1.0,0.0,-0.19436722,0.30603385
Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)",0.0,1.0,0.0,-0.19436722,0.30603385
Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA),0.0,1.0,0.0,-0.19436722,0.30603385
Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4),0.0,1.0,0.0,-0.19436722,0.30603385
Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX),0.0,1.0,0.0,-0.19436722,0.30603385
Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A),0.0,1.0,0.0,-0.19436722,0.30603385
Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)",0.0,1.0,0.0,-0.19436722,0.30603385
"Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)",0.0,1.0,0.0,-0.19436722,0.30603385
"Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)",0.0,1.0,0.0,-0.19436722,0.30603385
Defective DHDDS causes retinitis pigmentosa 59,0.0,1.0,0.0,-0.19436722,0.30603385
Defective DOLK causes DOLK-CDG (CDG-1m),0.0,1.0,0.0,-0.19436722,0.30603385
Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2,0.0,1.0,0.0,-0.19436722,0.30603385
Defective DPM1 causes DPM1-CDG (CDG-1e),0.0,1.0,0.0,-0.19436722,0.30603385
Defective DPM2 causes DPM2-CDG (CDG-1u),0.0,1.0,0.0,-0.19436722,0.30603385
Defective DPM3 causes DPM3-CDG (CDG-1o),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective EXT1 causes exostoses 1, TRPS2 and CHDS",2.2915096e-06,3.0,2.2915096e-06,-0.18766859,0.21982181
Defective EXT2 causes exostoses 2,2.384682e-07,3.0,2.384682e-07,-0.19367012,0.2152899
Defective FMO3 causes Trimethylaminuria (TMAU),0.0,1.0,0.0,-0.19436722,0.30603385
Defective GALE can cause Epimerase-deficiency galactosemia (EDG),0.0,1.0,0.0,-0.19436722,0.30603385
Defective GALK1 can cause Galactosemia II (GALCT2),0.0,1.0,0.0,-0.19436722,0.30603385
Defective GALNT12 causes colorectal cancer 1 (CRCS1),3.6116901e-07,3.0,3.6116901e-07,-0.19331144,0.21556073
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),5.406493e-09,3.0,5.406493e-09,-0.19435142,0.21477543
Defective GALT can cause Galactosemia,0.0,1.0,0.0,-0.19436722,0.30603385
Defective GCK causes maturity-onset diabetes of the young 2 (MODY2),0.0,1.0,0.0,-0.19436722,0.30603385
Defective GCLC causes Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD),0.0,1.0,0.0,-0.19436722,0.30603385
Defective GFPT1 causes CMSTA1,0.0,1.0,0.0,-0.19436722,0.30603385
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.19436722,0.30603385
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.19436722,0.30603385
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.19436722,0.30603385
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.19436722,0.30603385
Defective GIF causes intrinsic factor deficiency,0.0,1.0,0.0,-0.19436722,0.30603385
"Defective GNE causes sialuria, Nonaka myopathy and inclusion body myopathy 2",0.0,1.0,0.0,-0.19436722,0.30603385
Defective GSS causes Glutathione synthetase deficiency (GSS deficiency),0.0,1.0,0.0,-0.19436722,0.30603385
Defective HEXA causes GM2G1,0.0,1.0,0.0,-0.19436722,0.30603385
Defective HEXB causes GM2G2,0.0,1.0,0.0,-0.19436722,0.30603385
Defective HK1 causes hexokinase deficiency (HK deficiency),0.0,1.0,0.0,-0.19436722,0.30603385
Defective HLCS causes multiple carboxylase deficiency,6.5731833e-06,6.0,6.5731833e-06,-0.17515226,0.09236766
Defective LARGE causes MDDGA6 and MDDGB6,0.0,1.0,0.0,-0.19436722,0.30603385
Defective LFNG causes SCDO3,3.073063e-09,4.0,3.073063e-09,-0.19435824,0.16913506
Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF,0.0,1.0,0.0,-0.19436722,0.30603385
Defective MAN1B1 causes MRT15,0.0,1.0,0.0,-0.19436722,0.30603385
Defective MAOA causes Brunner syndrome (BRUNS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective MAT1A causes Methionine adenosyltransferase deficiency (MATD),0.0,1.0,0.0,-0.19436722,0.30603385
Defective MGAT2 causes MGAT2-CDG (CDG-2a),0.0,1.0,0.0,-0.19436722,0.30603385
Defective MMAA causes methylmalonic aciduria type cblA,1.147911e-05,2.0,1.147911e-05,-0.16081108,0.2857378
Defective MMAB causes methylmalonic aciduria type cblB,0.0,1.0,0.0,-0.19436722,0.30603385
Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC,3.769002e-08,2.0,3.769002e-08,-0.19425705,0.26048186
Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD,6.053782e-06,3.0,6.053782e-06,-0.1766706,0.22812667
Defective MOGS causes MOGS-CDG (CDG-2b),0.0,1.0,0.0,-0.19436722,0.30603385
Defective MPDU1 causes MPDU1-CDG (CDG-1f),0.0,1.0,0.0,-0.19436722,0.30603385
Defective MPI causes MPI-CDG (CDG-1b),0.0,1.0,0.0,-0.19436722,0.30603385
Defective MTR causes methylmalonic aciduria and homocystinuria type cblG,9.53085e-06,3.0,9.53085e-06,-0.1665063,0.23580201
Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE,1.5418301e-07,3.0,1.5418301e-07,-0.1939165,0.21510386
Defective MUT causes methylmalonic aciduria mut type,0.0,1.0,0.0,-0.19436722,0.30603385
Defective Mismatch Repair Associated With MLH1,8.178542e-06,3.0,8.178542e-06,-0.17045942,0.23281689
Defective Mismatch Repair Associated With MSH2,1.2278513e-05,3.0,1.2278513e-05,-0.15847424,0.24186721
Defective Mismatch Repair Associated With MSH3,4.3822987e-10,2.0,4.3822987e-10,-0.19436595,0.26039964
Defective Mismatch Repair Associated With MSH6,2.551994e-10,2.0,2.551994e-10,-0.19436647,0.26039922
Defective Mismatch Repair Associated With PMS2,4.0925283e-07,3.0,4.0925283e-07,-0.19317089,0.21566689
Defective NEU1 causes sialidosis,0.0,1.0,0.0,-0.19436722,0.30603385
Defective OPLAH causes 5-oxoprolinase deficiency (OPLAHD),0.0,1.0,0.0,-0.19436722,0.30603385
Defective PAPSS2 causes SEMD-PA,0.0,1.0,0.0,-0.19436722,0.30603385
Defective PGM1 causes PGM1-CDG (CDG1t),0.0,1.0,0.0,-0.19436722,0.30603385
Defective PMM2 causes PMM2-CDG (CDG-1a),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3",4.1298733e-08,2.0,4.1298733e-08,-0.1942465,0.26048985
"Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1",8.181728e-08,2.0,8.181728e-08,-0.19412805,0.2605793
"Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2",3.1934182e-09,2.0,3.1934182e-09,-0.19435789,0.26040572
Defective RFT1 causes RFT1-CDG (CDG-1n),0.0,1.0,0.0,-0.19436722,0.30603385
Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)",0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC12A1 causes Bartter syndrome 1 (BS1),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC12A3 causes Gitelman syndrome (GS),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN)",0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC17A5 causes Salla disease (SD) and ISSD,0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC1A3 causes episodic ataxia 6 (EA6),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC26A2 causes chondrodysplasias,0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC26A4 causes Pendred syndrome (PDS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC2A10 causes arterial tortuosity syndrome (ATS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC2A9 causes hypouricemia renal 2 (RHUC2),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC33A1 causes spastic paraplegia 42 (SPG42),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS)",0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC35D1 causes Schneckenbecken dysplasia (SCHBCKD),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ)",0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC3A1 causes cystinuria (CSNU),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0,1.0,0.0,-0.19436722,0.30603385
"Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)",0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC5A2 causes renal glucosuria (GLYS1),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A2 causes orthostatic intolerance (OI),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC6A5 causes hyperekplexia 3 (HKPX3),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC7A9 causes cystinuria (CSNU),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH)",0.0,1.0,0.0,-0.19436722,0.30603385
Defective SLC9A9 causes autism 16 (AUTS16),0.0,1.0,0.0,-0.19436722,0.30603385
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",4.1227446e-10,2.0,4.1227446e-10,-0.19436601,0.26039958
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",4.1227446e-10,1.0,4.1227446e-10,-0.19436601,0.30603474
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,2.0,0.0,-0.19436722,0.2603987
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,1.0,0.0,-0.19436722,0.30603385
"Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)",2.2023929e-13,2.0,2.2023929e-13,-0.19436722,0.2603987
"Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)",0.0,1.0,0.0,-0.19436722,0.30603385
Defective SRD5A3 causes SRD5A3-CDG (CDG-1q) and KHRZ,0.0,1.0,0.0,-0.19436722,0.30603385
Defective ST3GAL3 causes MCT12 and EIEE15,0.0,1.0,0.0,-0.19436722,0.30603385
Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD),0.0,1.0,0.0,-0.19436722,0.30603385
Defective TCN2 causes hereditary megaloblastic anemia,3.1753927e-08,2.0,3.1753927e-08,-0.1942744,0.26046878
Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency),0.0,1.0,0.0,-0.19436722,0.30603385
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC),0.0,1.0,0.0,-0.19436722,0.30603385
Defective UGT1A1 causes hyperbilirubinemia,0.0,1.0,0.0,-0.19436722,0.30603385
Defective UGT1A4 causes hyperbilirubinemia,0.0,1.0,0.0,-0.19436722,0.30603385
Defective pro-SFTPB causes pulmonary surfactant metabolism dysfunction 1 (SMDP1) and respiratory distress syndrome (RDS),1.478717e-07,4.0,1.478717e-07,-0.19393496,0.16945471
Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS),5.271978e-06,2.0,5.271978e-06,-0.17895599,0.2720361
Degradation of AXIN,2.0129097e-07,34.0,2.0129097e-07,-0.1937788,-1.1994826
Degradation of DVL,9.188649e-06,35.0,9.188649e-06,-0.16750664,-1.225279
Degradation of GABA,1.3477991e-07,2.0,1.3477991e-07,-0.19397323,0.2606962
Degradation of GLI1 by the proteasome,1.1253192e-05,36.0,1.1253192e-05,-0.16147149,-1.2663568
Degradation of GLI2 by the proteasome,2.1727442e-06,35.0,2.1727442e-06,-0.18801577,-1.2407659
Deletions in the AMER1 gene destabilize the destruction complex,5.806921e-08,2.0,5.806921e-08,-0.19419748,0.26052687
Deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling,3.081912e-08,2.0,3.081912e-08,-0.19427712,0.26046672
Deposition of new CENPA-containing nucleosomes at the centromere,3.6169175e-07,20.0,3.6169175e-07,-0.1933099,-0.5602361
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,2.2408922e-05,14.0,2.2408922e-05,-0.12886067,-0.2377577
Dermatan sulfate biosynthesis,2.0009238e-06,4.0,2.0009238e-06,-0.18851805,0.17354517
Detoxification of Reactive Oxygen Species,0.00011203808,12.0,0.00011203808,0.13314645,0.051361118
Digestion of dietary carbohydrate,9.055864e-05,5.0,9.055864e-05,0.07035701,0.3233934
Digestion of dietary lipid,2.7759584e-09,3.0,2.7759584e-09,-0.1943591,0.21476963
Dimerization of procaspase-8,2.12152e-08,8.0,2.12152e-08,-0.1943052,-0.013365549
Disassembly of the destruction complex and recruitment of AXIN to the membrane,1.0794467e-05,19.0,1.0794467e-05,-0.16281246,-0.4915715
Disinhibition of SNARE formation,2.7326024e-07,3.0,2.7326024e-07,-0.19356841,0.21536669
Displacement of DNA glycosylase by APEX1,9.159262e-06,8.0,9.159262e-06,-0.16759254,0.006805876
Dissolution of Fibrin Clot,4.0645534e-07,3.0,4.0645534e-07,-0.19317906,0.2156607
Dopamine Neurotransmitter Release Cycle,5.3494106e-05,7.0,5.3494106e-05,-0.037991352,0.15030631
Downregulation of ERBB2:ERBB3 signaling,1.3736219e-07,10.0,1.3736219e-07,-0.19396567,-0.10437953
Downregulation of ERBB4 signaling,2.1168544e-06,7.0,2.1168544e-06,-0.18817917,0.036895547
Downregulation of SMAD2/3:SMAD4 transcriptional activity,6.9228963e-06,18.0,6.9228963e-06,-0.17412996,-0.45448247
Downregulation of TGF-beta receptor signaling,1.8782472e-08,19.0,1.8782472e-08,-0.19431232,-0.51535785
Downstream TCR signaling,3.5410565e-08,56.0,3.5410565e-08,-0.1942637,-2.2038226
Downstream signal transduction,8.716129e-06,24.0,8.716129e-06,-0.16888793,-0.7243351
Downstream signaling of activated FGFR1,1.5574951e-05,14.0,1.5574951e-05,-0.14883797,-0.25284308
Downstream signaling of activated FGFR2,0.00014106477,14.0,0.00014106477,0.21799831,0.024164645
Downstream signaling of activated FGFR3,0.0008213408,14.0,0.0008213408,2.2066052,1.525814
Downstream signaling of activated FGFR4,0.00010202671,15.0,0.00010202671,0.10388087,-0.10764362
Dual Incision in GG-NER,0.00015280322,30.0,0.00015280322,0.25231254,-0.68008655
Dual incision in TC-NER,3.428956e-05,48.0,3.428956e-05,-0.09413077,-1.763128
E2F mediated regulation of DNA replication,5.8676756e-06,15.0,5.8676756e-06,-0.17721462,-0.31990623
E3 ubiquitin ligases ubiquitinate target proteins,4.0981995e-05,31.0,4.0981995e-05,-0.0745672,-0.9725573
ECM proteoglycans,4.6845198e-05,13.0,4.6845198e-05,-0.05742768,-0.13818161
EGFR downregulation,2.1130163e-05,17.0,2.1130163e-05,-0.13259877,-0.37748596
EGFR interacts with phospholipase C-gamma,1.4105561e-07,3.0,1.4105561e-07,-0.19395487,0.21507485
EPH-ephrin mediated repulsion of cells,8.448928e-09,28.0,8.448928e-09,-0.19434252,-0.92609715
EPHA-mediated growth cone collapse,6.91734e-08,10.0,6.91734e-08,-0.194165,-0.10453006
EPHB-mediated forward signaling,1.1726482e-08,26.0,1.1726482e-08,-0.19433293,-0.8348196
ER-Phagosome pathway,1.4655173e-08,45.0,1.4655173e-08,-0.19432439,-1.7018816
ERBB2 Activates PTK6 Signaling,4.6846966e-05,6.0,4.6846966e-05,-0.05742251,0.18126851
ERBB2 Regulates Cell Motility,7.108853e-05,7.0,7.108853e-05,0.013441285,0.18914446
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,1.0863884e-05,17.0,1.0863884e-05,-0.16260953,-0.40014786
Early Phase of HIV Life Cycle,2.5267e-05,7.0,2.5267e-05,-0.12050583,0.08799747
Eicosanoid ligand-binding receptors,0.0,1.0,0.0,-0.19436722,0.30603385
Eicosanoids,0.0005007732,2.0,0.0005007732,1.2695107,1.3658115
Electric Transmission Across Gap Junctions,1.0839593e-06,3.0,1.0839593e-06,-0.19119856,0.21715623
Electron transport from NADPH to Ferredoxin,1.6385419e-06,3.0,1.6385419e-06,-0.18957739,0.21838042
Elevation of cytosolic Ca2+ levels,3.3073134e-06,5.0,3.3073134e-06,-0.18469916,0.13079374
Endogenous sterols,2.9560144e-06,4.0,2.9560144e-06,-0.18572609,0.17565344
Endosomal Sorting Complex Required For Transport (ESCRT),1.2943052e-05,23.0,1.2943052e-05,-0.15653163,-0.6693694
Endosomal/Vacuolar pathway,2.7146356e-07,7.0,2.7146356e-07,-0.19357367,0.032822017
Energy dependent regulation of mTOR by LKB1-AMPK,8.623971e-06,23.0,8.623971e-06,-0.16915733,-0.6789034
Entry of Influenza Virion into Host Cell via Endocytosis,0.0,1.0,0.0,-0.19436722,0.30603385
Enzymatic degradation of Dopamine by monoamine oxidase,3.0950018e-10,2.0,3.0950018e-10,-0.1943663,0.26039937
Enzymatic degradation of dopamine by COMT,1.8931863e-09,2.0,1.8931863e-09,-0.19436169,0.26040286
Ephrin signaling,9.390703e-09,12.0,9.390703e-09,-0.19433977,-0.19593236
Erythrocytes take up carbon dioxide and release oxygen,2.4196574e-06,7.0,2.4196574e-06,-0.18729399,0.03756396
Erythrocytes take up oxygen and release carbon dioxide,3.8159737e-07,4.0,3.8159737e-07,-0.19325173,0.16997063
Essential fructosuria,0.0,1.0,0.0,-0.19436722,0.30603385
Essential pentosuria,0.0,1.0,0.0,-0.19436722,0.30603385
Establishment of Sister Chromatid Cohesion,5.6621734e-06,7.0,5.6621734e-06,-0.17781536,0.044721533
Estrogen biosynthesis,0.0,1.0,0.0,-0.19436722,0.30603385
Estrogen-dependent gene expression,0.00093330827,72.0,0.00093330827,2.5339127,-0.87386763
Ethanol oxidation,0.00030004347,5.0,0.00030004347,0.6827305,0.7858127
Eukaryotic Translation Termination,2.1432788e-08,33.0,2.1432788e-08,-0.19430456,-1.1542444
Export of Viral Ribonucleoproteins from Nucleus,3.3265115e-09,3.0,3.3265115e-09,-0.1943575,0.21477084
Extrinsic Pathway of Fibrin Clot Formation,1.8755787e-07,2.0,1.8755787e-07,-0.19381894,0.2608127
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis,1.7908664e-07,34.0,1.7908664e-07,-0.19384372,-1.1995317
FCERI mediated Ca+2 mobilization,2.7318389e-05,18.0,2.7318389e-05,-0.114509135,-0.4094612
FCERI mediated MAPK activation,3.686452e-06,21.0,3.686452e-06,-0.18359086,-0.59853214
FCERI mediated NF-kB activation,4.7140184e-05,53.0,4.7140184e-05,-0.056565367,-1.9629375
FCGR activation,8.319055e-09,7.0,8.319055e-09,-0.19434291,0.032241143
FGFR1 ligand binding and activation,2.5397048e-05,3.0,2.5397048e-05,-0.120125666,0.27082524
FGFR1 mutant receptor activation,2.2006647e-08,17.0,2.2006647e-08,-0.19430289,-0.4240804
FGFR2 alternative splicing,0.0027203346,18.0,0.0027203346,7.7578115,5.5351353
FGFR2 ligand binding and activation,0.00016243877,3.0,0.00016243877,0.28047952,0.5733328
FGFR2 mutant receptor activation,7.8703096e-08,14.0,7.8703096e-08,-0.19413716,-0.2870497
FGFR3 ligand binding and activation,0.0001840243,3.0,0.0001840243,0.34357914,0.620981
FGFR4 ligand binding and activation,5.6982135e-05,4.0,5.6982135e-05,-0.027795024,0.29491135
FGFR4 mutant receptor activation,0.0,1.0,0.0,-0.19436722,0.30603385
FGFRL1 modulation of FGFR1 signaling,1.9068151e-05,3.0,1.9068151e-05,-0.13862652,0.25685474
FMO oxidises nucleophiles,4.229582e-07,2.0,4.229582e-07,-0.1931308,0.2613323
Fanconi Anemia Pathway,3.642753e-05,18.0,3.642753e-05,-0.08788098,-0.38935357
FasL/ CD95L signaling,5.891061e-10,4.0,5.891061e-10,-0.1943655,0.1691296
Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion,3.927216e-08,6.0,3.927216e-08,-0.1942524,0.077944644
Fatty acids,4.0523806e-05,2.0,4.0523806e-05,-0.0759066,0.34985143
Fibronectin matrix formation,0.0,1.0,0.0,-0.19436722,0.30603385
Folding of actin by CCT/TriC,1.8291933e-06,7.0,1.8291933e-06,-0.18902007,0.036260556
Formation of ATP by chemiosmotic coupling,0.0,1.0,0.0,-0.19436722,0.30603385
Formation of Incision Complex in GG-NER,0.00013593772,33.0,0.00013593772,0.20301074,-0.85422117
Formation of RNA Pol II elongation complex ,7.731007e-08,42.0,7.731007e-08,-0.19414124,-1.5648377
Formation of Senescence-Associated Heterochromatin Foci (SAHF),1.6284525e-07,7.0,1.6284525e-07,-0.1938912,0.032582242
Formation of TC-NER Pre-Incision Complex,4.7892368e-06,43.0,4.7892368e-06,-0.18036714,-1.6000717
Formation of a pool of free 40S subunits,4.3527275e-06,41.0,4.3527275e-06,-0.18164317,-1.5097649
Formation of editosomes by ADAR proteins,5.9178156e-09,2.0,5.9178156e-09,-0.19434993,0.2604117
Formation of selenosugars for excretion,0.0,1.0,0.0,-0.19436722,0.30603385
Formation of the Early Elongation Complex,1.4536116e-06,26.0,1.4536116e-06,-0.19011797,-0.83163685
Formation of the Editosome,4.981553e-08,3.0,4.981553e-08,-0.19422159,0.21487348
"Formation of the active cofactor, UDP-glucuronate",0.0,1.0,0.0,-0.19436722,0.30603385
Formation of the cornified envelope,6.395783e-07,21.0,6.395783e-07,-0.19249758,-0.6052578
"Formation of the ternary complex, and subsequently, the 43S complex",5.176777e-06,26.0,5.176777e-06,-0.17923428,-0.8234182
Formation of tubulin folding intermediates by CCT/TriC,1.7221461e-06,11.0,1.7221461e-06,-0.18933298,-0.14651643
Formation of xylulose-5-phosphate,2.204955e-08,3.0,2.204955e-08,-0.19430277,0.21481216
Free fatty acid receptors,9.26645e-08,2.0,9.26645e-08,-0.19409633,0.26060325
Fructose biosynthesis,1.5525941e-06,3.0,1.5525941e-06,-0.18982862,0.21819071
Fructose catabolism,3.8067815e-06,5.0,3.8067815e-06,-0.1832391,0.13189626
Fusion and Uncoating of the Influenza Virion,0.0,1.0,0.0,-0.19436722,0.30603385
G alpha (12/13) signalling events,9.777277e-07,46.0,9.777277e-07,-0.19150908,-1.7453909
G alpha (z) signalling events,1.2865324e-06,17.0,1.2865324e-06,-0.19060637,-0.42128906
G beta:gamma signalling through PI3Kgamma,1.50220685e-05,14.0,1.50220685e-05,-0.15045418,-0.25406352
G beta:gamma signalling through PLC beta,3.2362448e-06,12.0,3.2362448e-06,-0.18490691,-0.18880935
G1/S-Specific Transcription,1.696968e-05,8.0,1.696968e-05,-0.14476085,0.024046691
G2 Phase,1.839048e-06,3.0,1.839048e-06,-0.18899125,0.21882303
G2/M DNA replication checkpoint,1.3678482e-06,2.0,1.3678482e-06,-0.19036867,0.2634181
GAB1 signalosome,9.989189e-05,8.0,9.989189e-05,0.0976403,0.20709018
GABA A (rho) receptor activation,0.0,1.0,0.0,-0.19436722,0.30603385
GABA A receptor activation,5.6535987e-07,3.0,5.6535987e-07,-0.19271456,0.21601146
GABA B receptor activation,0.0016617437,16.0,0.0016617437,4.663301,3.2896597
GABA synthesis,0.0,1.0,0.0,-0.19436722,0.30603385
GLI proteins bind promoters of Hh responsive genes to promote transcription,5.5375557e-07,2.0,5.5375557e-07,-0.19274846,0.26162106
GLI3 is processed to GLI3R by the proteasome,1.7542952e-06,36.0,1.7542952e-06,-0.189239,-1.2873248
GP1b-IX-V activation signalling,2.284823e-06,6.0,2.284823e-06,-0.18768814,0.0829015
GPVI-mediated activation cascade,2.0984937e-06,22.0,2.0984937e-06,-0.18823282,-0.6476726
GRB2 events in EGFR signaling,2.7801814e-06,5.0,2.7801814e-06,-0.1862401,0.12963013
GRB2 events in ERBB2 signaling,1.3719337e-05,8.0,1.3719337e-05,-0.15426236,0.016871845
GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00011673956,7.0,0.00011673956,0.14689,0.2899151
GRB7 events in ERBB2 signaling,3.726787e-07,4.0,3.726787e-07,-0.19327778,0.16995096
GTP hydrolysis and joining of the 60S ribosomal subunit,8.233343e-06,49.0,8.233343e-06,-0.17029922,-1.8662802
Galactose catabolism,3.3145633e-07,5.0,3.3145633e-07,-0.1933983,0.1242248
Gamma-carboxylation of protein precursors,0.0,1.0,0.0,-0.19436722,0.30603385
Gap junction assembly,2.3492541e-05,3.0,2.3492541e-05,-0.125693,0.2666212
Gap junction degradation,1.9599348e-07,6.0,1.9599348e-07,-0.1937943,0.07829059
Gap-filling DNA repair synthesis and ligation in GG-NER,7.015951e-08,18.0,7.015951e-08,-0.19416212,-0.46960926
Gap-filling DNA repair synthesis and ligation in TC-NER,1.1592953e-05,48.0,1.1592953e-05,-0.16047828,-1.813229
Gastrin-CREB signalling pathway via PKC and MAPK,1.2532169e-07,11.0,1.2532169e-07,-0.19400087,-0.15004127
Generation of second messenger molecules,5.743577e-10,13.0,5.743577e-10,-0.19436555,-0.241587
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,6.2338677e-06,16.0,6.2338677e-06,-0.17614417,-0.36473307
Glucagon-type ligand receptors,2.7918633e-08,11.0,2.7918633e-08,-0.19428562,-0.15025629
Glucocorticoid biosynthesis,0.0,1.0,0.0,-0.19436722,0.30603385
Gluconeogenesis,1.952719e-07,20.0,1.952719e-07,-0.1937964,-0.56060344
Glutamate Neurotransmitter Release Cycle,0.00010444652,8.0,0.00010444652,0.11095454,0.21714413
Glutathione synthesis and recycling,3.844276e-07,6.0,3.844276e-07,-0.19324346,0.07870653
Glycerophospholipid catabolism,9.254691e-06,4.0,9.254691e-06,-0.16731358,0.18955721
Glycine degradation,1.463429e-07,3.0,1.463429e-07,-0.19393943,0.21508653
Glycogen breakdown (glycogenolysis),1.1567917e-07,13.0,1.1567917e-07,-0.19402906,-0.2413329
Glycogen storage disease type 0 (liver GYS2),0.0,1.0,0.0,-0.19436722,0.30603385
Glycogen storage disease type 0 (muscle GYS1),4.8569807e-05,3.0,4.8569807e-05,-0.05238624,0.32197708
Glycogen storage disease type II (GAA),1.0029024e-06,2.0,1.0029024e-06,-0.1914355,0.2626125
Glycogen storage disease type IV (GBE1),0.0,1.0,0.0,-0.19436722,0.30603385
Glycogen storage disease type Ia (G6PC),0.0,1.0,0.0,-0.19436722,0.30603385
Glycogen storage disease type Ib (SLC37A4),0.0,1.0,0.0,-0.19436722,0.30603385
Glycogen storage disease type XV (GYG1),2.7713272e-06,3.0,2.7713272e-06,-0.18626599,0.22088094
Glycogen synthesis,6.8900874e-08,10.0,6.8900874e-08,-0.1941658,-0.10453065
Glycoprotein hormones,0.0,1.0,0.0,-0.19436722,0.30603385
Glycosphingolipid metabolism,1.0750111e-06,20.0,1.0750111e-06,-0.19122472,-0.5586615
Golgi Associated Vesicle Biogenesis,2.3196314e-07,43.0,2.3196314e-07,-0.19368914,-1.6101314
Golgi Cisternae Pericentriolar Stack Reorganization,8.4280735e-05,10.0,8.4280735e-05,0.05200521,0.081359565
Growth hormone receptor signaling,2.8671304e-06,13.0,2.8671304e-06,-0.18598594,-0.23525932
HATs acetylate histones,4.3983342e-05,61.0,4.3983342e-05,-0.06579356,-2.3349874
HCN channels,1.7214688e-06,3.0,1.7214688e-06,-0.18933496,0.21856348
HDACs deacetylate histones,8.246754e-05,26.0,8.246754e-05,0.046704806,-0.6528056
HDL assembly,7.200819e-05,4.0,7.200819e-05,0.016129665,0.32808006
HDL clearance,2.5860152e-06,3.0,2.5860152e-06,-0.18680769,0.22047189
HDL remodeling,6.820271e-07,4.0,6.820271e-07,-0.1923735,0.17063381
HDMs demethylate histones,9.861313e-07,19.0,9.861313e-07,-0.19148453,-0.5132225
HDR through Homologous Recombination (HRR),6.142773e-07,42.0,6.142773e-07,-0.19257154,-1.5636523
HDR through MMEJ (alt-NHEJ),5.4120164e-06,8.0,5.4120164e-06,-0.17854662,-0.0014658411
HDR through Single Strand Annealing (SSA),4.778846e-06,24.0,4.778846e-06,-0.18039753,-0.73302627
HHAT G278V abrogates palmitoylation of Hh-Np,0.0,1.0,0.0,-0.19436722,0.30603385
HS-GAG biosynthesis,9.113068e-05,10.0,9.113068e-05,0.0720292,0.09648021
HS-GAG degradation,1.0877136e-06,6.0,1.0877136e-06,-0.19118758,0.08025898
HSF1 activation,3.6802203e-06,11.0,3.6802203e-06,-0.18360907,-0.14219415
HSP90 chaperone cycle for steroid hormone receptors (SHR),5.7130893e-07,14.0,5.7130893e-07,-0.19269715,-0.2859623
Heme biosynthesis,9.335125e-08,7.0,9.335125e-08,-0.19409433,0.032428853
Heme degradation,6.983633e-10,3.0,6.983633e-10,-0.19436517,0.21476501
Hereditary fructose intolerance,0.0,1.0,0.0,-0.19436722,0.30603385
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD,6.468099e-08,35.0,6.468099e-08,-0.19417813,-1.2454193
Histidine catabolism,1.479391e-05,5.0,1.479391e-05,-0.15112114,0.15614939
Hormone ligand-binding receptors,1.2196653e-10,2.0,1.2196653e-10,-0.19436686,0.26039895
HuR (ELAVL1) binds and stabilizes mRNA,2.3316673e-07,8.0,2.3316673e-07,-0.19368562,-0.012897695
Hyaluronan biosynthesis and export,0.0,1.0,0.0,-0.19436722,0.30603385
Hyaluronan uptake and degradation,9.285623e-06,8.0,9.285623e-06,-0.16722317,0.007084799
Hydrolysis of LPC,4.389169e-07,4.0,4.389169e-07,-0.19308417,0.17009716
Hydrolysis of LPE,6.770509e-08,2.0,6.770509e-08,-0.19416931,0.26054814
Hydroxycarboxylic acid-binding receptors,0.0,1.0,0.0,-0.19436722,0.30603385
Hypusine synthesis from eIF5A-lysine,2.337627e-07,5.0,2.337627e-07,-0.19368388,0.12400914
IKBKB deficiency causes SCID,8.1336526e-07,2.0,8.1336526e-07,-0.19198957,0.2621941
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR),4.7666848e-07,3.0,4.7666848e-07,-0.19297381,0.2158157
IL-6-type cytokine receptor ligand interactions,6.656346e-05,6.0,6.656346e-05,0.0002134378,0.22479093
IP3 and IP4 transport between cytosol and nucleus,0.0,1.0,0.0,-0.19436722,0.30603385
IP6 and IP7 transport between cytosol and nucleus,0.0,1.0,0.0,-0.19436722,0.30603385
IPs transport between ER lumen and cytosol,0.0,1.0,0.0,-0.19436722,0.30603385
IPs transport between ER lumen and nucleus,0.0,1.0,0.0,-0.19436722,0.30603385
IPs transport between cytosol and ER lumen,0.0,1.0,0.0,-0.19436722,0.30603385
IPs transport between nucleus and ER lumen,0.0,1.0,0.0,-0.19436722,0.30603385
IPs transport between nucleus and cytosol,0.0,1.0,0.0,-0.19436722,0.30603385
IRAK4 deficiency (TLR2/4),1.681288e-06,5.0,1.681288e-06,-0.18945242,0.12720442
IRAK4 deficiency (TLR5),2.4764526e-07,4.0,2.4764526e-07,-0.1936433,0.16967495
IRF3 mediated activation of type 1 IFN,5.1351867e-07,3.0,5.1351867e-07,-0.19286609,0.21589704
IRF3-mediated induction of type I IFN,3.1261576e-09,3.0,3.1261576e-09,-0.19435808,0.2147704
IRS activation,3.0182093e-11,3.0,3.0182093e-11,-0.19436714,0.21476357
IRS-mediated signalling,2.5745647e-08,22.0,2.5745647e-08,-0.19429196,-0.65224797
ISG15 antiviral mechanism,0.00084358605,55.0,0.00084358605,2.2716334,-0.29612347
IkBA variant leads to EDA-ID,1.6002787e-05,7.0,1.6002787e-05,-0.14758731,0.06754753
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,2.9716648e-07,27.0,2.9716648e-07,-0.19349854,-0.87982476
Import of palmitoyl-CoA into the mitochondrial matrix,9.2208895e-05,8.0,9.2208895e-05,0.07518109,0.19013065
Inactivation of APC/C via direct inhibition of the APC/C complex,0.00042463452,14.0,0.00042463452,1.0469395,0.65011996
Inactivation of CDC42 and RAC1,5.384179e-08,5.0,5.384179e-08,-0.19420983,0.12361198
Influenza Viral RNA Transcription and Replication,3.901346e-06,53.0,3.901346e-06,-0.18296267,-2.0583832
Influenza Virus Induced Apoptosis,0.0,1.0,0.0,-0.19436722,0.30603385
Inhibition of Signaling by Overexpressed EGFR,1.5520052e-10,2.0,1.5520052e-10,-0.19436677,0.260399
Inhibition of TSC complex formation by PKB,3.9952704e-07,3.0,3.9952704e-07,-0.1931993,0.21564542
InlA-mediated entry of Listeria monocytogenes into host cells,9.098958e-07,7.0,9.098958e-07,-0.19170739,0.034231294
InlB-mediated entry of Listeria monocytogenes into host cell,2.8930795e-06,12.0,2.8930795e-06,-0.18591006,-0.18956687
Inositol transporters,9.521971e-06,2.0,9.521971e-06,-0.16653225,0.28141758
Insulin effects increased synthesis of Xylulose-5-Phosphate,4.3728136e-07,2.0,4.3728136e-07,-0.19308895,0.26136395
Insulin processing,2.019413e-06,17.0,2.019413e-06,-0.188464,-0.41967127
Insulin receptor recycling,4.2527074e-05,14.0,4.2527074e-05,-0.070050575,-0.19334865
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA,1.6851664e-05,6.0,1.6851664e-05,-0.14510584,0.11505651
Integrin cell surface interactions,0.0021354472,15.0,0.0021354472,6.048048,4.3809533
Interaction With Cumulus Cells,0.0,1.0,0.0,-0.19436722,0.30603385
Interaction With The Zona Pellucida,3.960673e-09,2.0,3.960673e-09,-0.19435565,0.26040742
Interaction between L1 and Ankyrins,2.9903577e-10,7.0,2.9903577e-10,-0.19436635,0.03222344
Interaction between PHLDA1 and AURKA,0.0,1.0,0.0,-0.19436722,0.30603385
Interactions of Rev with host cellular proteins,3.4541936e-05,27.0,3.4541936e-05,-0.09339301,-0.80423236
Interactions of Tat with host cellular proteins,1.8393788e-06,2.0,1.8393788e-06,-0.1889903,0.26445892
Interactions of Vpr with host cellular proteins,1.0539802e-05,27.0,1.0539802e-05,-0.16355689,-0.857215
Interconversion of 2-oxoglutarate and 2-hydroxyglutarate,4.5884233e-05,4.0,4.5884233e-05,-0.060236804,0.27041373
Interconversion of nucleotide di- and triphosphates,0.0002487658,12.0,0.0002487658,0.5328338,0.35317558
Interconversion of polyamines,0.0,1.0,0.0,-0.19436722,0.30603385
Interleukin receptor SHC signaling,7.2805365e-06,13.0,7.2805365e-06,-0.1730845,-0.22551711
Interleukin-1 processing,1.3615538e-06,2.0,1.3615538e-06,-0.19038707,0.26340422
Interleukin-10 signaling,1.6309477e-07,5.0,1.6309477e-07,-0.19389045,0.123853154
Interleukin-12 signaling,1.4983173e-07,23.0,1.4983173e-07,-0.19392923,-0.69760925
Interleukin-15 signaling,7.600387e-09,9.0,7.600387e-09,-0.194345,-0.059030786
Interleukin-18 signaling,9.495982e-08,2.0,9.495982e-08,-0.19408964,0.2606083
Interleukin-2 signaling,2.1722259e-07,8.0,2.1722259e-07,-0.19373222,-0.0129328845
Interleukin-20 family signaling,2.2615755e-08,10.0,2.2615755e-08,-0.19430111,-0.10463283
Interleukin-21 signaling,2.5728688e-09,6.0,2.5728688e-09,-0.19435969,0.07786363
Interleukin-23 signaling,6.700277e-08,4.0,6.700277e-08,-0.19417135,0.16927621
Interleukin-27 signaling,2.4584002e-08,8.0,2.4584002e-08,-0.19429535,-0.013358118
Interleukin-33 signaling,2.5417378e-06,2.0,2.5417378e-06,-0.18693712,0.26600933
Interleukin-35 Signalling,1.7217427e-08,8.0,1.7217427e-08,-0.1943169,-0.013374384
Interleukin-36 pathway,1.564115e-06,3.0,1.564115e-06,-0.18979496,0.21821614
Interleukin-37 signaling,3.0179777e-05,15.0,3.0179777e-05,-0.10614463,-0.26623937
Interleukin-38 signaling,1.8082387e-08,2.0,1.8082387e-08,-0.19431436,0.2604386
Interleukin-4 and Interleukin-13 signaling,2.8137796e-05,43.0,2.8137796e-05,-0.112113826,-1.5485318
Interleukin-6 signaling,2.4665207e-05,8.0,2.4665207e-05,-0.12226502,0.041033886
Interleukin-7 signaling,0.00035935317,14.0,0.00035935317,0.8561067,0.5060171
Interleukin-9 signaling,8.380497e-07,6.0,8.380497e-07,-0.19191739,0.079707876
Intestinal hexose absorption,0.0,1.0,0.0,-0.19436722,0.30603385
Intestinal infectious diseases,0.0,1.0,0.0,-0.19436722,0.30603385
Intestinal lipid absorption,0.0,1.0,0.0,-0.19436722,0.30603385
Intestinal saccharidase deficiencies,0.0,1.0,0.0,-0.19436722,0.30603385
Intra-Golgi traffic,1.24436665e-05,29.0,1.24436665e-05,-0.15799145,-0.94428277
Intracellular oxygen transport,0.0,1.0,0.0,-0.19436722,0.30603385
Intraflagellar transport,7.00095e-05,25.0,7.00095e-05,0.010287021,-0.63467056
Intrinsic Pathway of Fibrin Clot Formation,1.1451115e-05,4.0,1.1451115e-05,-0.16089292,0.19440563
Invadopodia formation,2.3172802e-08,4.0,2.3172802e-08,-0.19429947,0.16917945
Ion homeostasis,3.5798735e-07,12.0,3.5798735e-07,-0.19332075,-0.19516285
Ion influx/efflux at host-pathogen interface,6.0881985e-07,3.0,6.0881985e-07,-0.19258748,0.21610741
Ion transport by P-type ATPases,1.8334802e-05,18.0,1.8334802e-05,-0.14077027,-0.4292917
Ionotropic activity of kainate receptors,1.2221827e-07,4.0,1.2221827e-07,-0.19400994,0.16939808
Josephin domain DUBs,2.3006722e-05,6.0,2.3006722e-05,-0.12711315,0.12864327
KSRP (KHSRP) binds and destabilizes mRNA,2.0377616e-05,13.0,2.0377616e-05,-0.13479866,-0.19660646
Keratan sulfate biosynthesis,0.000105617364,10.0,0.000105617364,0.1143772,0.1284583
Keratan sulfate degradation,6.5581145e-05,3.0,6.5581145e-05,-0.0026580929,0.35952812
Kinesins,5.0717917e-06,14.0,5.0717917e-06,-0.17954117,-0.2760279
L13a-mediated translational silencing of Ceruloplasmin expression,7.905217e-05,49.0,7.905217e-05,0.036720894,-1.7099538
LDL clearance,3.2154253e-06,12.0,3.2154253e-06,-0.18496777,-0.18885532
LDL remodeling,0.0,1.0,0.0,-0.19436722,0.30603385
LGI-ADAM interactions,4.2300215e-08,4.0,4.2300215e-08,-0.19424357,0.16922167
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,5.6243252e-06,5.0,5.6243252e-06,-0.17792599,0.13590832
Lactose synthesis,2.5910134e-07,3.0,2.5910134e-07,-0.1936098,0.21533544
Laminin interactions,1.4648547e-06,7.0,1.4648547e-06,-0.19008511,0.03545632
Late Phase of HIV Life Cycle,9.545324e-06,97.0,9.84054e-08,-0.19407955,-4.053873
Ligand-receptor interactions,0.0,1.0,0.0,-0.19436722,0.30603385
Linoleic acid (LA) metabolism,5.136586e-07,4.0,5.136586e-07,-0.19286567,0.17026216
Lipid particle organization,3.9632577e-09,3.0,3.9632577e-09,-0.19435562,0.21477225
Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.0,1.0,0.0,-0.19436722,0.30603385
Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling,3.8051471e-06,6.0,3.8051471e-06,-0.18324389,0.08625747
Lysine catabolism,1.2296962e-05,8.0,1.2296962e-05,-0.15842031,0.013732069
Lysosomal oligosaccharide catabolism,5.0843262e-08,5.0,5.0843262e-08,-0.19421859,0.12360536
Lysosome Vesicle Biogenesis,6.507471e-07,22.0,6.507471e-07,-0.19246493,-0.6508683
Lysosphingolipid and LPA receptors,4.7876533e-06,6.0,4.7876533e-06,-0.18037179,0.08842627
MAP kinase activation,1.01964215e-05,46.0,1.01964215e-05,-0.16456068,-1.7250414
MAP2K and MAPK activation,0.0004258995,24.0,0.0004258995,1.0506372,0.19656044
MAPK1 (ERK2) activation,0.00033763348,3.0,0.00033763348,0.79261494,0.96005976
MAPK3 (ERK1) activation,0.00018953509,3.0,0.00018953509,0.3596885,0.6331456
MAPK6/MAPK4 signaling,8.155305e-05,55.0,8.155305e-05,0.04403155,-1.9782444
MASTL Facilitates Mitotic Progression,4.181762e-05,8.0,4.181762e-05,-0.072124474,0.078896336
MET Receptor Activation,5.3008944e-07,2.0,5.3008944e-07,-0.19281764,0.2615688
MET activates PI3K/AKT signaling,2.0819225e-05,5.0,2.0819225e-05,-0.13350773,0.16944973
MET activates PTK2 signaling,2.570994e-09,4.0,2.570994e-09,-0.1943597,0.16913396
MET activates PTPN11,7.2022467e-06,4.0,7.2022467e-06,-0.17331336,0.18502662
MET activates RAP1 and RAC1,3.7550378e-06,10.0,3.7550378e-06,-0.18339036,-0.09639384
MET activates RAS signaling,0.00012841403,8.0,0.00012841403,0.18101722,0.27005032
MET activates STAT3,1.4714415e-07,3.0,1.4714415e-07,-0.1939371,0.2150883
MET interacts with TNS proteins,1.6334176e-09,2.0,1.6334176e-09,-0.19436246,0.26040226
MET receptor recycling,8.517251e-06,6.0,8.517251e-06,-0.1694693,0.096659034
MGMT-mediated DNA damage reversal,9.7719076e-11,2.0,9.7719076e-11,-0.19436695,0.2603989
MHC class II antigen presentation,2.1738867e-06,56.0,2.1738867e-06,-0.18801244,-2.1991022
MPS I - Hurler syndrome,0.0,1.0,0.0,-0.19436722,0.30603385
MPS II - Hunter syndrome,0.0,1.0,0.0,-0.19436722,0.30603385
MPS IIIA - Sanfilippo syndrome A,0.0,1.0,0.0,-0.19436722,0.30603385
MPS IIIB - Sanfilippo syndrome B,0.0,1.0,0.0,-0.19436722,0.30603385
MPS IIIC - Sanfilippo syndrome C,0.0,1.0,0.0,-0.19436722,0.30603385
MPS IIID - Sanfilippo syndrome D,0.0,1.0,0.0,-0.19436722,0.30603385
MPS IV - Morquio syndrome A,0.0,1.0,0.0,-0.19436722,0.30603385
MPS IV - Morquio syndrome B,0.0,1.0,0.0,-0.19436722,0.30603385
MPS IX - Natowicz syndrome,0.0,1.0,0.0,-0.19436722,0.30603385
MPS VI - Maroteaux-Lamy syndrome,0.0,1.0,0.0,-0.19436722,0.30603385
MPS VII - Sly syndrome,0.0,1.0,0.0,-0.19436722,0.30603385
MTF1 activates gene expression,7.4435933e-09,3.0,7.4435933e-09,-0.19434546,0.21477993
Macroautophagy,1.3177607e-05,42.0,1.3177607e-05,-0.15584597,-1.5359199
Major pathway of rRNA processing in the nucleolus and cytosol,0.00011545005,88.0,0.00011545005,0.14312045,-3.4093807
Meiotic recombination,0.0005886501,20.0,0.0005886501,1.5263957,0.738359
Meiotic synapsis,5.5170563e-06,24.0,5.5170563e-06,-0.17823957,-0.7313968
Melanin biosynthesis,0.0,1.0,0.0,-0.19436722,0.30603385
Metabolism of Angiotensinogen to Angiotensins,2.7711244e-06,3.0,2.7711244e-06,-0.18626659,0.2208805
Metabolism of folate and pterines,1.0515911e-06,10.0,1.0515911e-06,-0.19129317,-0.102361456
Metabolism of ingested H2SeO4 and H2SeO3 into H2Se,1.4937687e-05,4.0,1.4937687e-05,-0.15070085,0.20210195
Metabolism of ingested MeSeO2H into MeSeH,1.7902349e-07,2.0,1.7902349e-07,-0.19384389,0.26079386
"Metabolism of ingested SeMet, Sec, MeSec into H2Se",3.132772e-07,6.0,3.132772e-07,-0.19345145,0.07854947
Metabolism of serotonin,2.2701947e-07,2.0,2.2701947e-07,-0.19370359,0.2608998
Metabolism of vitamin K,2.1195074e-05,3.0,2.1195074e-05,-0.13240902,0.26154977
Metal sequestration by antimicrobial proteins,0.0,1.0,0.0,-0.19436722,0.30603385
Metalloprotease DUBs,0.00014573321,17.0,0.00014573321,0.23164527,-0.1024357
Metallothioneins bind metals,0.0,1.0,0.0,-0.19436722,0.30603385
Methionine salvage pathway,0.00053496263,6.0,0.00053496263,1.3694545,1.258741
Methylation,3.2682616e-05,9.0,3.2682616e-05,-0.09882824,0.013096436
Methylation of MeSeH for excretion,0.0,1.0,0.0,-0.19436722,0.30603385
MicroRNA (miRNA) biogenesis,4.351242e-07,16.0,4.351242e-07,-0.19309525,-0.37753326
Mineralocorticoid biosynthesis,0.0,1.0,0.0,-0.19436722,0.30603385
Miscellaneous substrates,3.2184573e-05,3.0,3.2184573e-05,-0.10028414,0.2858081
Miscellaneous transport and binding events,4.177711e-05,15.0,4.177711e-05,-0.072242886,-0.2406393
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta),2.393535e-08,10.0,2.393535e-08,-0.19429724,-0.10462989
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha),4.369931e-08,11.0,4.369931e-08,-0.19423948,-0.15022145
Misspliced GSK3beta mutants stabilize beta-catenin,2.2997156e-07,11.0,2.2997156e-07,-0.19369496,-0.14981027
Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling,1.0485059e-07,3.0,1.0485059e-07,-0.19406071,0.21499495
Mitochondrial ABC transporters,1.8830111e-06,4.0,1.8830111e-06,-0.18886274,0.17328489
Mitochondrial protein import,9.8417e-07,36.0,9.8417e-07,-0.19149026,-1.2890248
Mitochondrial tRNA aminoacylation,0.0019129069,15.0,0.0019129069,5.3975096,3.8897152
Mitochondrial transcription initiation,1.2684825e-06,3.0,1.2684825e-06,-0.19065915,0.21756355
Mitochondrial transcription termination,5.3590746e-08,2.0,5.3590746e-08,-0.19421057,0.26051697
Mitochondrial translation elongation,6.5913327e-06,50.0,6.5913327e-06,-0.1750992,-1.91554
Mitochondrial translation initiation,1.1689349e-06,50.0,1.1689349e-06,-0.19095016,-1.9275094
Mitochondrial translation termination,7.930651e-05,50.0,7.930651e-05,0.037464384,-1.7550277
Mitotic Anaphase,5.9228832e-06,104.0,5.69508e-08,-0.19420074,-4.3813148
Mitotic Metaphase/Anaphase Transition,1.8912306e-08,2.0,1.8912306e-08,-0.19431195,0.2604404
Molecules associated with elastic fibres,2.4488416e-05,11.0,2.4488416e-05,-0.12278182,-0.096261896
Molybdenum cofactor biosynthesis,3.256919e-07,4.0,3.256919e-07,-0.19341514,0.16984724
Mtb iron assimilation by chelation,0.0,1.0,0.0,-0.19436722,0.30603385
Multifunctional anion exchangers,2.1656095e-09,2.0,2.1656095e-09,-0.19436088,0.26040345
MyD88 deficiency (TLR2/4),1.7642449e-06,4.0,1.7642449e-06,-0.18920992,0.17302272
MyD88 deficiency (TLR5),7.075268e-09,2.0,7.075268e-09,-0.19434655,0.2604143
MyD88 dependent cascade initiated on endosome,4.217363e-05,54.0,4.217363e-05,-0.07108377,-2.0195358
MyD88-independent TLR4 cascade ,1.3393863e-07,63.0,1.3393863e-07,-0.19397569,-2.5230513
Myoclonic epilepsy of Lafora,7.324723e-06,7.0,7.324723e-06,-0.17295533,0.048391465
N-glycan antennae elongation in the medial/trans-Golgi,3.67467e-05,12.0,3.67467e-05,-0.08694796,-0.11483799
N-glycan trimming and elongation in the cis-Golgi,2.0001762e-06,4.0,2.0001762e-06,-0.18852024,0.17354351
NADE modulates death signalling,3.772836e-08,5.0,3.772836e-08,-0.19425693,0.1235764
NADPH regeneration,2.5795967e-07,2.0,2.5795967e-07,-0.19361314,0.2609681
NCAM1 interactions,2.7577789e-08,13.0,2.7577789e-08,-0.19428661,-0.24152738
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,6.3763773e-06,10.0,6.3763773e-06,-0.17572758,-0.09060745
NF-kB is activated and signals survival,1.6205359e-08,11.0,1.6205359e-08,-0.19431986,-0.15028214
NFG and proNGF binds to p75NTR,1.0671626e-09,2.0,1.0671626e-09,-0.1943641,0.26040104
NGF processing,0.00056612963,3.0,0.00056612963,1.460563,1.4644449
NIK-->noncanonical NF-kB signaling,0.000112560934,36.0,0.000112560934,0.13467489,-1.0427289
NOD1/2 Signaling Pathway,5.184748e-05,25.0,5.184748e-05,-0.042804826,-0.6747616
NOSIP mediated eNOS trafficking,0.0,1.0,0.0,-0.19436722,0.30603385
NOSTRIN mediated eNOS trafficking,1.3981823e-06,4.0,1.3981823e-06,-0.19028,0.17221466
NOTCH1 Intracellular Domain Regulates Transcription,3.2358857e-06,31.0,3.2358857e-06,-0.18490796,-1.0558784
NOTCH2 Activation and Transmission of Signal to the Nucleus,9.871039e-06,16.0,9.871039e-06,-0.16551186,-0.35670432
NOTCH2 intracellular domain regulates transcription,1.1244078e-06,8.0,1.1244078e-06,-0.19108032,-0.010930359
NOTCH3 Intracellular Domain Regulates Transcription,1.39347565e-08,15.0,1.39347565e-08,-0.19432649,-0.33282784
NOTCH4 Activation and Transmission of Signal to the Nucleus,5.773339e-06,8.0,5.773339e-06,-0.1774904,-0.0006682426
NOTCH4 Intracellular Domain Regulates Transcription,4.1075164e-05,9.0,4.1075164e-05,-0.07429485,0.031622242
NR1D1 (REV-ERBA) represses gene expression,1.7122992e-09,3.0,1.7122992e-09,-0.19436222,0.21476728
NRAGE signals death through JNK,1.496188e-06,32.0,1.496188e-06,-0.1899935,-1.1053538
NRIF signals cell death from the nucleus,4.7480313e-07,13.0,4.7480313e-07,-0.19297926,-0.24054016
NS1 Mediated Effects on Host Pathways,6.251348e-06,29.0,6.251348e-06,-0.17609306,-0.9579518
NTF3 activates NTRK2 (TRKB) signaling,0.0,1.0,0.0,-0.19436722,0.30603385
NTF3 activates NTRK3 signaling,0.0,1.0,0.0,-0.19436722,0.30603385
NTF4 activates NTRK2 (TRKB) signaling,0.0,1.0,0.0,-0.19436722,0.30603385
NTRK3 as a dependence receptor,0.0007316659,3.0,0.0007316659,1.9444644,1.8298515
Na+/Cl- dependent neurotransmitter transporters,4.101532e-06,4.0,4.101532e-06,-0.18237749,0.17818205
Nectin/Necl  trans heterodimerization,5.794482e-10,2.0,5.794482e-10,-0.19436552,0.26039997
Neddylation,6.2308277e-07,141.0,4.419027e-09,-0.19435431,-6.0815153
Negative regulation of FGFR1 signaling,3.2484738e-06,18.0,3.2484738e-06,-0.18487117,-0.46259344
Negative regulation of FGFR2 signaling,0.0026923465,18.0,0.0026923465,7.6759953,5.473354
Negative regulation of FGFR3 signaling,0.0019145932,18.0,0.0019145932,5.402439,3.7565322
Negative regulation of FGFR4 signaling,0.00013717778,19.0,0.00013717778,0.20663571,-0.21259141
Negative regulation of MAPK pathway,4.660012e-05,25.0,4.660012e-05,-0.058144104,-0.6863447
Negative regulation of MET activity,0.0019219619,17.0,0.0019219619,5.4239798,3.8184333
Negative regulation of NOTCH4 signaling,3.8143824e-08,35.0,3.8143824e-08,-0.19425572,-1.2454778
Negative regulation of TCF-dependent signaling by DVL-interacting proteins,2.5686355e-09,4.0,2.5686355e-09,-0.1943597,0.16913396
Negative regulation of TCF-dependent signaling by WNT ligand antagonists,4.5468614e-06,4.0,4.5468614e-06,-0.18107568,0.1791651
Negative regulation of activity of TFAP2 (AP-2) family transcription factors,8.381755e-07,6.0,8.381755e-07,-0.19191703,0.079708144
Negative regulators of DDX58/IFIH1 signaling,0.0007191977,28.0,0.0007191977,1.9080169,0.6614498
Nephrin family interactions,3.3857517e-10,12.0,3.3857517e-10,-0.19436622,-0.19595233
Netrin mediated repulsion signals,1.3107803e-09,4.0,1.3107803e-09,-0.19436339,0.16913119
Neurexins and neuroligins,2.2423812e-06,17.0,2.2423812e-06,-0.18781221,-0.4191791
Neurofascin interactions,2.0906292e-11,4.0,2.0906292e-11,-0.19436716,0.16912834
Neurophilin interactions with VEGF and VEGFR,0.0,1.0,0.0,-0.19436722,0.30603385
Neutrophil degranulation,0.00046021072,239.0,1.9255679e-06,-0.18873833,-9.539264
Nicotinamide salvaging,8.512682e-07,7.0,8.512682e-07,-0.19187877,0.03410188
NoRC negatively regulates rRNA expression,2.2648721e-05,40.0,2.2648721e-05,-0.12815967,-1.4237429
Noncanonical activation of NOTCH3,2.5323927e-09,6.0,2.5323927e-09,-0.19435982,0.07786354
Nonhomologous End-Joining (NHEJ),3.4678233e-05,25.0,3.4678233e-05,-0.092994586,-0.7126612
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC),5.0790426e-05,51.0,5.0790426e-05,-0.045894846,-1.8636094
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC),1.3049752e-05,36.0,1.3049752e-05,-0.15621974,-1.2623911
Norepinephrine Neurotransmitter Release Cycle,9.80217e-07,6.0,9.80217e-07,-0.19150181,0.08002169
Notch-HLH transcription pathway,1.5310799e-07,12.0,1.5310799e-07,-0.19391964,-0.19561511
NrCAM interactions,9.871399e-10,4.0,9.871399e-10,-0.19436432,0.16913047
Nuclear Envelope Breakdown,3.8523278e-05,33.0,3.8523278e-05,-0.08175461,-1.069255
Nuclear Events (kinase and transcription factor activation),0.000771011,19.0,0.000771011,2.0594795,1.1865398
Nuclear Receptor transcription pathway,1.8206075e-06,28.0,1.8206075e-06,-0.18904516,-0.9220971
Nuclear signaling by ERBB4,0.00024409499,13.0,0.00024409499,0.51917994,0.29722998
Nucleotide-like (purinergic) receptors,6.5497824e-07,4.0,6.5497824e-07,-0.19245255,0.1705741
O-glycosylation of TSR domain-containing proteins,3.5539343e-09,3.0,3.5539343e-09,-0.19435684,0.21477133
Olfactory Signaling Pathway,2.2853583e-09,36.0,2.2853583e-09,-0.19436054,-1.2911922
Oncogene Induced Senescence,0.00011254128,23.0,0.00011254128,0.13461745,-0.44951504
Opioid Signalling,6.0725515e-06,41.0,6.0725515e-06,-0.17661573,-1.5059685
Opsins,4.6212456e-08,3.0,4.6212456e-08,-0.19423214,0.2148655
Orc1 removal from chromatin,1.4366665e-07,46.0,1.4366665e-07,-0.19394726,-1.747232
Organic anion transport,2.1791682e-06,2.0,2.1791682e-06,-0.18799698,0.26520902
Organic anion transporters,2.828805e-12,2.0,2.828805e-12,-0.19436722,0.2603987
Organic cation transport,1.3910648e-07,2.0,1.3910648e-07,-0.19396058,0.26070577
Other interleukin signaling,0.00074298144,14.0,0.00074298144,1.9775425,1.3528428
Other semaphorin interactions,6.0162165e-08,6.0,6.0162165e-08,-0.19419134,0.07799075
Ovarian tumor domain proteases,9.83893e-07,25.0,9.83893e-07,-0.19149107,-0.78703845
Oxidative Stress Induced Senescence,2.1169e-06,47.0,2.1169e-06,-0.18817902,-1.7885112
Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha,3.3307174e-08,3.0,3.3307174e-08,-0.19426985,0.214837
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,4.78946e-06,37.0,4.78946e-06,-0.18036652,-1.3262601
PAOs oxidise polyamines to amines,0.0,1.0,0.0,-0.19436722,0.30603385
PCNA-Dependent Long Patch Base Excision Repair,0.00010710487,15.0,0.00010710487,0.11872552,-0.09643403
PD-1 signaling,3.7345287e-09,6.0,3.7345287e-09,-0.1943563,0.07786618
PECAM1 interactions,7.694704e-06,10.0,7.694704e-06,-0.1718738,-0.08769736
PI and PC transport between ER and Golgi membranes,7.289048e-07,3.0,7.289048e-07,-0.19223645,0.21637248
PI3K events in ERBB2 signaling,3.2687701e-06,8.0,3.2687701e-06,-0.18481185,-0.0061968677
PI3K events in ERBB4 signaling,9.977858e-07,5.0,9.977858e-07,-0.19145045,0.12569566
PI3K/AKT activation,0.0012717199,7.0,0.0012717199,3.5231693,2.8394327
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",2.6227812e-05,46.0,2.6227812e-05,-0.11769715,-1.6896535
PIPs transport between Golgi and plasma membranes,0.0,1.0,0.0,-0.19436722,0.30603385
PIPs transport between early and late endosome membranes,0.0,1.0,0.0,-0.19436722,0.30603385
PIPs transport between early endosome and Golgi membranes,0.0,1.0,0.0,-0.19436722,0.30603385
PIPs transport between late endosome and Golgi membranes,0.0,1.0,0.0,-0.19436722,0.30603385
PIPs transport between plasma and early endosome membranes,0.0,1.0,0.0,-0.19436722,0.30603385
PIWI-interacting RNA (piRNA) biogenesis,8.931681e-05,12.0,8.931681e-05,0.06672684,0.0012059173
PKA activation in glucagon signalling,3.6851798e-05,7.0,3.6851798e-05,-0.08664074,0.113569885
PKA-mediated phosphorylation of key metabolic factors,6.1178757e-11,2.0,6.1178757e-11,-0.19436705,0.2603988
PKMTs methylate histone lysines,1.02140075e-05,32.0,1.02140075e-05,-0.16450927,-1.08611
PLC-gamma1 signalling,2.2382406e-05,2.0,2.2382406e-05,-0.12893818,0.30980587
PLCG1 events in ERBB2 signaling,1.6625061e-06,4.0,1.6625061e-06,-0.18950732,0.17279813
POLB-Dependent Long Patch Base Excision Repair,6.413559e-05,7.0,6.413559e-05,-0.0068837996,0.17379646
"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",3.5167556e-11,4.0,3.5167556e-11,-0.19436711,0.16912837
"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation",3.991321e-09,3.0,3.991321e-09,-0.19435555,0.2147723
PP2A-mediated dephosphorylation of key metabolic factors,2.1779245e-09,5.0,2.1779245e-09,-0.19436087,0.12349794
PPARA activates gene expression,1.5602559e-06,20.0,1.5602559e-06,-0.18980622,-0.55759037
PRC2 methylates histones and DNA,2.4912631e-05,19.0,2.4912631e-05,-0.12154173,-0.46040684
PTEN Loss of Function in Cancer,0.0,1.0,0.0,-0.19436722,0.30603385
PTK6 Activates STAT3,1.9671843e-07,3.0,1.9671843e-07,-0.19379216,0.21519774
PTK6 Down-Regulation,2.0731227e-07,3.0,2.0731227e-07,-0.1937612,0.21522114
PTK6 Expression,2.1636142e-09,5.0,2.1636142e-09,-0.1943609,0.1234979
PTK6 Regulates Cell Cycle,8.453315e-06,7.0,8.453315e-06,-0.16965619,0.050882738
PTK6 Regulates Proteins Involved in RNA Processing,4.951137e-08,4.0,4.951137e-08,-0.19422248,0.1692376
"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",5.871605e-06,11.0,5.871605e-06,-0.17720315,-0.13735686
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1,2.8370604e-08,9.0,2.8370604e-08,-0.19428429,-0.05898495
PTK6 promotes HIF1A stabilization,2.010862e-08,4.0,2.010862e-08,-0.19430843,0.16917269
Packaging Of Telomere Ends,5.2963674e-08,12.0,5.2963674e-08,-0.1942124,-0.19583616
Paradoxical activation of RAF signaling by kinase inactive BRAF,9.429669e-05,23.0,9.429669e-05,0.081284195,-0.48978838
Passive transport by Aquaporins,1.2326122e-11,3.0,1.2326122e-11,-0.19436717,0.21476352
Peptide chain elongation,8.022007e-07,32.0,8.022007e-07,-0.19202219,-1.1068858
Peptide ligand-binding receptors,2.765775e-07,31.0,2.765775e-07,-0.19355871,-1.062411
Phase 0 - rapid depolarisation,9.858107e-08,10.0,9.858107e-08,-0.19407904,-0.104465134
Phase 1 - inactivation of fast Na+ channels,6.868794e-09,5.0,6.868794e-09,-0.19434714,0.12350829
Phase 2 - plateau phase,5.886813e-07,11.0,5.886813e-07,-0.19264635,-0.14901845
Phase 3 - rapid repolarisation,1.4905817e-09,4.0,1.4905817e-09,-0.19436286,0.16913159
Phase 4 - resting membrane potential,5.700805e-05,5.0,5.700805e-05,-0.027719274,0.24933341
Phenylalanine and tyrosine catabolism,7.5615793e-07,5.0,7.5615793e-07,-0.19215678,0.12516229
Phenylketonuria,0.0,1.0,0.0,-0.19436722,0.30603385
Phosphate bond hydrolysis by NTPDase proteins,0.00028145502,5.0,0.00028145502,0.6283921,0.74478036
Phosphate bond hydrolysis by NUDT proteins,1.4754345e-07,6.0,1.4754345e-07,-0.19393592,0.07818363
Phosphorylation of CD3 and TCR zeta chains,2.7847006e-08,6.0,2.7847006e-08,-0.19428582,0.07791941
Physiological factors,1.9948831e-07,2.0,1.9948831e-07,-0.19378407,0.26083902
Pink/Parkin Mediated Mitophagy,2.0738646e-05,16.0,2.0738646e-05,-0.13374327,-0.33271503
Plasmalogen biosynthesis,3.6678841e-06,3.0,3.6678841e-06,-0.18364513,0.22286002
Platelet Adhesion to exposed collagen,4.0792973e-08,7.0,4.0792973e-08,-0.19424796,0.032312844
Platelet degranulation ,9.172129e-06,54.0,9.172129e-06,-0.16755493,-2.0923836
Platelet sensitization by LDL,2.9836212e-07,10.0,2.9836212e-07,-0.19349504,-0.104024135
Polo-like kinase mediated events,9.12238e-06,7.0,9.12238e-06,-0.16770035,0.052359644
Polymerase switching,1.1276407e-07,11.0,1.1276407e-07,-0.19403759,-0.150069
Post NMDA receptor activation events,9.293407e-06,17.0,9.293407e-06,-0.1672004,-0.40361455
Post-chaperonin tubulin folding pathway,3.1426658e-05,7.0,3.1426658e-05,-0.1024997,0.10159437
Post-transcriptional silencing by small RNAs,1.378113e-06,7.0,1.378113e-06,-0.19033869,0.035264842
Post-translational protein phosphorylation,1.9527402e-05,36.0,1.9527402e-05,-0.13728403,-1.2480923
Potassium transport channels,8.397849e-07,3.0,8.397849e-07,-0.19191234,0.21661726
Pre-NOTCH Processing in Golgi,5.8171157e-05,7.0,5.8171157e-05,-0.024319232,0.1606305
Pre-NOTCH Processing in the Endoplasmic Reticulum,1.8651751e-06,6.0,1.8651751e-06,-0.18891487,0.08197516
Pre-NOTCH Transcription and Translation,0.00016327872,34.0,0.00016327872,0.2829349,-0.8395035
Prefoldin mediated transfer of substrate  to CCT/TriC,3.9471678e-07,14.0,3.9471678e-07,-0.19321337,-0.28635213
Pregnenolone biosynthesis,1.35973205e-05,6.0,1.35973205e-05,-0.15461905,0.10787284
Presynaptic depolarization and calcium channel opening,1.0353269e-05,7.0,1.0353269e-05,-0.16410218,0.05507672
Presynaptic function of Kainate receptors,4.2108213e-06,12.0,4.2108213e-06,-0.18205799,-0.18665808
Processing of DNA double-strand break ends,6.5477293e-06,44.0,6.5477293e-06,-0.17522667,-1.6418251
Processing of Intronless Pre-mRNAs,5.8179376e-07,14.0,5.8179376e-07,-0.1926665,-0.2859392
Processing of SMDT1,2.9155824e-05,9.0,2.9155824e-05,-0.10913788,0.005311349
Processive synthesis on the lagging strand,1.03518126e-07,11.0,1.03518126e-07,-0.19406462,-0.15008941
Prolactin receptor signaling,2.0884183e-06,9.0,2.0884183e-06,-0.18826228,-0.054437574
Proline catabolism,0.0,1.0,0.0,-0.19436722,0.30603385
Propionyl-CoA catabolism,3.2269762e-07,5.0,3.2269762e-07,-0.1934239,0.124205455
Prostacyclin signalling through prostacyclin receptor,1.2204649e-05,11.0,1.2204649e-05,-0.15869015,-0.12337723
Protein methylation,6.4370556e-07,8.0,6.4370556e-07,-0.19248553,-0.011991464
Protein repair,2.1737596e-07,4.0,2.1737596e-07,-0.19373178,0.16960815
Proton-coupled monocarboxylate transport,2.5311315e-06,2.0,2.5311315e-06,-0.18696813,0.26598594
Proton-coupled neutral amino acid transporters,0.0,1.0,0.0,-0.19436722,0.30603385
Proton/oligopeptide cotransporters,1.7814267e-08,2.0,1.7814267e-08,-0.19431515,0.260438
Purine ribonucleoside monophosphate biosynthesis,1.0287467e-07,10.0,1.0287467e-07,-0.1940665,-0.10445566
Purine salvage,0.00075034914,8.0,0.00075034914,1.99908,1.6429174
Pyrimidine biosynthesis,6.604123e-08,2.0,6.604123e-08,-0.19417416,0.26054448
Pyrimidine catabolism,1.485161e-05,3.0,1.485161e-05,-0.15095246,0.24754712
Pyrimidine salvage,9.151553e-05,6.0,9.151553e-05,0.073154226,0.27987045
Pyrophosphate hydrolysis,1.7347156e-12,2.0,1.7347156e-12,-0.19436722,0.2603987
RA biosynthesis pathway,1.5287846e-05,10.0,1.5287846e-05,-0.14967725,-0.07093617
RAB GEFs exchange GTP for GDP on RABs,0.0002696421,63.0,0.0002696421,0.59386015,-1.9281356
RAB geranylgeranylation,2.3262437e-05,42.0,2.3262437e-05,-0.12636565,-1.5136585
RAF activation,6.328487e-06,18.0,6.328487e-06,-0.17586757,-0.45579457
RAS signaling downstream of NF1 loss-of-function variants,3.2436358e-06,5.0,3.2436358e-06,-0.18488531,0.13065317
RET signaling,3.4918795e-09,20.0,3.4918795e-09,-0.19435701,-0.56102675
RHO GTPases Activate Formins,3.906773e-05,66.0,3.906773e-05,-0.08016305,-2.574014
RHO GTPases Activate NADPH Oxidases,6.127581e-07,5.0,6.127581e-07,-0.19257598,0.12484575
RHO GTPases Activate ROCKs,0.0033894007,11.0,0.0033894007,9.713649,7.3314853
RHO GTPases Activate Rhotekin and Rhophilins,0.0002911733,6.0,0.0002911733,0.65680087,0.7205974
RHO GTPases Activate WASPs and WAVEs,0.00042400614,29.0,0.00042400614,1.0451026,-0.03579474
RHO GTPases activate CIT,0.00027743954,9.0,0.00027743954,0.6166539,0.55337584
RHO GTPases activate IQGAPs,1.5084069e-05,11.0,1.5084069e-05,-0.15027294,-0.117021166
RHO GTPases activate KTN1,0.00024242848,10.0,0.00024242848,0.51430833,0.43045685
RHO GTPases activate PAKs,1.3318058e-08,13.0,1.3318058e-08,-0.1943283,-0.24155885
RHO GTPases regulate CFTR trafficking,1.2562809e-08,2.0,1.2562809e-08,-0.19433048,0.26042643
RIP-mediated NFkB activation via ZBP1,1.7014228e-05,10.0,1.7014228e-05,-0.14463063,-0.06712532
RMTs methylate histone arginines,7.9701316e-08,27.0,7.9701316e-08,-0.19413424,-0.8803048
RNA Pol II CTD phosphorylation and interaction with CE,2.749645e-06,21.0,2.749645e-06,-0.18632936,-0.60060006
RNA Polymerase I Chain Elongation,4.883449e-06,19.0,4.883449e-06,-0.18009175,-0.5046195
RNA Polymerase I Promoter Escape,4.584183e-06,19.0,4.584183e-06,-0.18096659,-0.50528014
RNA Polymerase I Promoter Opening,3.84037e-09,3.0,3.84037e-09,-0.194356,0.21477199
RNA Polymerase I Transcription Initiation,2.760329e-08,21.0,2.760329e-08,-0.19428653,-0.60660875
RNA Polymerase I Transcription Termination,4.7265854e-05,20.0,4.7265854e-05,-0.056198,-0.45669925
RNA Polymerase II Pre-transcription Events,3.040236e-08,59.0,3.040236e-08,-0.19427836,-2.3407393
RNA Polymerase II Promoter Escape,8.646589e-08,35.0,8.646589e-08,-0.19411446,-1.2453711
RNA Polymerase II Transcription Initiation,1.7046877e-07,35.0,1.7046877e-07,-0.1938689,-1.2451857
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening,1.9511897e-05,35.0,1.9511897e-05,-0.13732934,-1.2024913
RNA Polymerase III Abortive And Retractive Initiation,2.2766001e-07,26.0,2.2766001e-07,-0.19370173,-0.834343
RNA Polymerase III Chain Elongation,5.8471873e-08,14.0,5.8471873e-08,-0.1941963,-0.28709435
RNA Polymerase III Transcription Initiation From Type 1 Promoter,3.5106563e-08,21.0,3.5106563e-08,-0.19426459,-0.6065922
RNA Polymerase III Transcription Initiation From Type 2 Promoter,3.6562687e-05,21.0,3.6562687e-05,-0.08748588,-0.52596074
RNA Polymerase III Transcription Initiation From Type 3 Promoter,4.5770294e-09,20.0,4.5770294e-09,-0.19435385,-0.56102437
RNA Polymerase III Transcription Termination,3.381423e-07,14.0,3.381423e-07,-0.19337875,-0.286477
RNA polymerase II transcribes snRNA genes,3.800631e-06,47.0,3.800631e-06,-0.18325707,-1.7847946
RNF mutants show enhanced WNT signaling and proliferation,2.8300354e-08,2.0,2.8300354e-08,-0.19428448,0.26046118
ROBO receptors bind AKAP5,2.9907852e-09,4.0,2.9907852e-09,-0.19435848,0.1691349
RORA activates gene expression,1.7517057e-07,4.0,1.7517057e-07,-0.19385517,0.16951497
"ROS, RNS production in phagocytes",3.8314465e-07,14.0,3.8314465e-07,-0.1932472,-0.28637767
RPIA deficiency: failed conversion of R5P to RU5P,0.0,1.0,0.0,-0.19436722,0.30603385
RPIA deficiency: failed conversion of RU5P to R5P,0.0,1.0,0.0,-0.19436722,0.30603385
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),3.6702865e-08,3.0,3.6702865e-08,-0.19425994,0.21484451
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,1.222926e-05,25.0,1.222926e-05,-0.15861821,-0.7622153
RUNX1 regulates estrogen receptor mediated transcription,3.201506e-07,7.0,3.201506e-07,-0.19343135,0.032929484
RUNX1 regulates expression of components of tight junctions,3.033264e-07,4.0,3.033264e-07,-0.19348052,0.16979787
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,2.1390058e-06,33.0,2.1390058e-06,-0.18811439,-1.1495701
RUNX1 regulates transcription of genes involved in BCR signaling,2.2097534e-08,5.0,2.2097534e-08,-0.19430262,0.12354191
RUNX1 regulates transcription of genes involved in WNT signaling,3.287118e-07,5.0,3.287118e-07,-0.19340631,0.12421873
RUNX1 regulates transcription of genes involved in differentiation of HSCs,3.1297736e-06,50.0,3.1297736e-06,-0.18521816,-1.9231809
RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,6.114837e-08,6.0,6.114837e-08,-0.19418848,0.07799292
RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,6.641909e-08,6.0,6.641909e-08,-0.19417305,0.078004576
RUNX1 regulates transcription of genes involved in interleukin signaling,5.561709e-09,4.0,5.561709e-09,-0.19435097,0.16914056
RUNX2 regulates bone development,5.695226e-07,16.0,5.695226e-07,-0.19270237,-0.3772366
RUNX2 regulates genes involved in cell migration,3.6531674e-07,6.0,3.6531674e-07,-0.19329931,0.078664355
RUNX2 regulates genes involved in differentiation of myeloid cells,1.7041381e-07,4.0,1.7041381e-07,-0.19386907,0.16950446
RUNX3 Regulates Immune Response and Cell Migration,2.6443754e-08,3.0,2.6443754e-08,-0.19428992,0.21482185
RUNX3 regulates BCL2L11 (BIM) transcription,3.9238475e-06,4.0,3.9238475e-06,-0.1828969,0.17778985
RUNX3 regulates CDKN1A transcription,1.8413666e-05,6.0,1.8413666e-05,-0.14053974,0.118504494
RUNX3 regulates NOTCH signaling,5.2820616e-07,11.0,5.2820616e-07,-0.19282316,-0.14915194
RUNX3 regulates RUNX1-mediated transcription,1.2850175e-07,3.0,1.2850175e-07,-0.19399159,0.21504714
RUNX3 regulates WNT signaling,1.1651982e-06,7.0,1.1651982e-06,-0.19096106,0.034794863
RUNX3 regulates YAP1-mediated transcription,1.6704103e-09,2.0,1.6704103e-09,-0.19436233,0.26040238
RUNX3 regulates p14-ARF,2.1931564e-07,5.0,2.1931564e-07,-0.1937261,0.123977266
Rap1 signalling,2.1698258e-06,8.0,2.1698258e-06,-0.1880243,-0.008622681
Receptor Mediated Mitophagy,2.585376e-05,10.0,2.585376e-05,-0.11879059,-0.04761284
Receptor-type tyrosine-protein phosphatases,0.00027302254,7.0,0.00027302254,0.60374194,0.6348961
Recognition and association of DNA glycosylase with site containing an affected purine,3.785384e-12,2.0,3.785384e-12,-0.1943672,0.2603987
Recognition and association of DNA glycosylase with site containing an affected pyrimidine,3.5759922e-09,8.0,3.5759922e-09,-0.19435678,-0.013404505
Recognition of DNA damage by PCNA-containing replication complex,0.0001780734,22.0,0.0001780734,0.32618326,-0.25922343
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,3.350797e-05,30.0,3.350797e-05,-0.096415535,-0.94342035
Recruitment of NuMA to mitotic centrosomes,5.8350703e-05,55.0,5.8350703e-05,-0.02379438,-2.0294616
Recycling of bile acids and salts,3.773612e-06,5.0,3.773612e-06,-0.18333606,0.13182305
Recycling of eIF2:GDP,8.0537893e-07,8.0,8.0537893e-07,-0.19201292,-0.011634596
Recycling pathway of L1,3.455063e-08,18.0,3.455063e-08,-0.19426621,-0.46968785
Reduction of cytosolic Ca++ levels,2.2044633e-06,4.0,2.2044633e-06,-0.18792306,0.17399445
Reelin signalling pathway,1.31156865e-11,3.0,1.31156865e-11,-0.19436717,0.21476352
Regulated proteolysis of p75NTR,1.5417163e-07,10.0,1.5417163e-07,-0.19391654,-0.10434243
Regulation by TREX1,0.0,1.0,0.0,-0.19436722,0.30603385
Regulation by c-FLIP,3.2002518e-08,9.0,3.2002518e-08,-0.19427368,-0.058976933
Regulation of Complement cascade,1.3716248e-06,7.0,1.3716248e-06,-0.19035763,0.035250533
Regulation of FZD by ubiquitination,1.8394767e-06,8.0,1.8394767e-06,-0.18899,-0.009351904
Regulation of Glucokinase by Glucokinase Regulatory Protein,1.1535787e-05,23.0,1.1535787e-05,-0.1606454,-0.6724758
Regulation of HSF1-mediated heat shock response,1.032494e-06,45.0,1.032494e-06,-0.191349,-1.6996348
Regulation of IFNA signaling,0.00026217126,10.0,0.00026217126,0.5720211,0.4740373
Regulation of IFNG signaling,0.00057885644,11.0,0.00057885644,1.4977665,1.1274569
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),5.788817e-07,36.0,5.788817e-07,-0.19267501,-1.2899194
Regulation of KIT signaling,0.0026291907,12.0,0.0026291907,7.4913764,5.607754
Regulation of PAK-2p34 activity by PS-GAP/RHG10,6.9701116e-08,3.0,6.9701116e-08,-0.19416346,0.21491736
Regulation of PLK1 Activity at G2/M Transition,0.00012589929,59.0,0.00012589929,0.17366603,-2.0628946
Regulation of PTEN gene transcription,0.00029235266,36.0,0.00029235266,0.66024846,-0.6458545
Regulation of PTEN localization,6.5232107e-06,8.0,6.5232107e-06,-0.17529835,0.0009870172
Regulation of PTEN mRNA translation,0.00032191875,10.0,0.00032191875,0.7466771,0.60592467
Regulation of PTEN stability and activity,1.9139641e-05,44.0,1.9139641e-05,-0.13841754,-1.6140295
Regulation of RAS by GAPs,6.4103756e-07,42.0,6.4103756e-07,-0.1924933,-1.5635933
Regulation of RUNX1 Expression and Activity,6.823923e-06,17.0,6.823923e-06,-0.17441928,-0.4090657
Regulation of RUNX2 expression and activity,1.7013033e-07,42.0,1.7013033e-07,-0.19386987,-1.5646329
Regulation of RUNX3 expression and activity,4.5206793e-08,32.0,4.5206793e-08,-0.19423507,-1.1085567
Regulation of TLR by endogenous ligand,3.5066148e-06,5.0,3.5066148e-06,-0.18411657,0.13123366
Regulation of TNFR1 signaling,4.228594e-07,22.0,4.228594e-07,-0.1931311,-0.6513714
Regulation of TP53 Activity,6.106354e-08,110.0,5.5512306e-10,-0.1943656,-4.6680655
Regulation of actin dynamics for phagocytic cup formation,4.3831724e-07,42.0,4.3831724e-07,-0.19308591,-1.5640409
Regulation of activated PAK-2p34 by proteasome mediated degradation,2.6306769e-05,31.0,2.6306769e-05,-0.11746634,-1.0049515
Regulation of commissural axon pathfinding by SLIT and ROBO,1.0606144e-10,2.0,1.0606144e-10,-0.1943669,0.26039892
Regulation of cortical dendrite branching,0.0,1.0,0.0,-0.19436722,0.30603385
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,1.3251229e-09,6.0,1.3251229e-09,-0.19436336,0.07786086
Regulation of expression of SLITs and ROBOs,3.0183834e-08,76.0,3.0183834e-08,-0.194279,-3.1165378
Regulation of gene expression by Hypoxia-inducible Factor,4.3016767e-06,7.0,4.3016767e-06,-0.18179241,0.041718364
Regulation of gene expression in early pancreatic precursor cells,0.0,1.0,0.0,-0.19436722,0.30603385
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells,0.0,1.0,0.0,-0.19436722,0.30603385
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,5.9736965e-11,2.0,5.9736965e-11,-0.19436705,0.2603988
Regulation of ornithine decarboxylase (ODC),0.00025060278,31.0,0.00025060278,0.5382037,-0.5098378
Regulation of pyruvate dehydrogenase (PDH) complex,4.5219283e-05,9.0,4.5219283e-05,-0.06218061,0.040770024
Regulation of signaling by CBL,2.0321497e-06,17.0,2.0321497e-06,-0.18842676,-0.41964313
Regulation of signaling by NODAL,2.8092344e-09,3.0,2.8092344e-09,-0.194359,0.21476968
Regulation of thyroid hormone activity,1.6882988e-06,2.0,1.6882988e-06,-0.18943192,0.26412547
Release of Hh-Np from the secreting cell,0.00021558336,3.0,0.00021558336,0.43583372,0.6906448
Release of apoptotic factors from the mitochondria,1.833547e-07,3.0,1.833547e-07,-0.19383124,0.21516824
Removal of aminoterminal propeptides from gamma-carboxylated proteins,2.1599956e-07,2.0,2.1599956e-07,-0.1937358,0.2608755
Repression of WNT target genes,0.00084267685,8.0,0.00084267685,2.2689755,1.8467226
Resolution of Sister Chromatid Cohesion,4.8425176e-05,57.0,4.8425176e-05,-0.05280903,-2.1426418
Retinoid metabolism and transport,4.758544e-06,13.0,4.758544e-06,-0.18045688,-0.2310842
Retinoid metabolism disease events,0.0,1.0,0.0,-0.19436722,0.30603385
Retrograde neurotrophin signalling,0.0062040887,9.0,0.0062040887,17.941645,13.635932
Retrograde transport at the Trans-Golgi-Network,3.8227296e-05,40.0,3.8227296e-05,-0.08261984,-1.3893545
Reuptake of GABA,0.0,1.0,0.0,-0.19436722,0.30603385
Reversible hydration of carbon dioxide,3.1314343e-07,4.0,3.1314343e-07,-0.19345184,0.16981953
Rhesus glycoproteins mediate ammonium transport.,8.1073654e-07,2.0,8.1073654e-07,-0.19199724,0.26218832
Rho GTPase cycle,2.194011e-05,67.0,2.194011e-05,-0.13023111,-2.6574569
Ribosomal scanning and start codon recognition,1.1923754e-06,31.0,1.1923754e-06,-0.19088162,-1.0603894
Role of ABL in ROBO-SLIT signaling,1.920517e-07,5.0,1.920517e-07,-0.19380581,0.123917066
Role of LAT2/NTAL/LAB on calcium mobilization,2.0845441e-08,11.0,2.0845441e-08,-0.19430628,-0.15027189
Role of phospholipids in phagocytosis,1.7105226e-08,14.0,1.7105226e-08,-0.19431722,-0.28718567
Role of second messengers in netrin-1 signaling,1.6133169e-12,4.0,1.6133169e-12,-0.19436722,0.1691283
S33 mutants of beta-catenin aren't phosphorylated,6.510332e-05,11.0,6.510332e-05,-0.004054893,-0.006608062
S37 mutants of beta-catenin aren't phosphorylated,7.3619657e-07,11.0,7.3619657e-07,-0.19221514,-0.14869282
S45 mutants of beta-catenin aren't phosphorylated,0.00022716366,11.0,0.00022716366,0.46968567,0.35112593
SCF(Skp2)-mediated degradation of p27/p21,3.0234503e-06,38.0,3.0234503e-06,-0.18552896,-1.3757936
SDK interactions,0.0,1.0,0.0,-0.19436722,0.30603385
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,7.7661977e-10,7.0,7.7661977e-10,-0.19436495,0.032224502
SHC-related events triggered by IGF1R,0.00017844817,5.0,0.00017844817,0.3272788,0.5174018
SHC1 events in EGFR signaling,4.629821e-05,6.0,4.629821e-05,-0.059026655,0.18005717
SHC1 events in ERBB2 signaling,2.2297552e-05,12.0,2.2297552e-05,-0.12918623,-0.1467332
SHC1 events in ERBB4 signaling,2.2044056e-05,7.0,2.2044056e-05,-0.12992725,0.08088309
SIRT1 negatively regulates rRNA expression,0.0001708018,13.0,0.0001708018,0.30492663,0.13544169
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,8.488595e-08,7.0,8.488595e-08,-0.19411907,0.032410163
SLBP independent Processing of Histone Pre-mRNAs,9.061938e-05,7.0,9.061938e-05,0.070534565,0.23225713
SLIT2:ROBO1 increases RHOA activity,1.582971e-10,2.0,1.582971e-10,-0.19436675,0.260399
SMAC-mediated apoptotic response,4.6711296e-10,6.0,4.6711296e-10,-0.19436586,0.07785898
SMAD2/3 MH2 Domain Mutants in Cancer,1.0915236e-05,6.0,1.0915236e-05,-0.16245942,0.101952374
SMAD2/3 Phosphorylation Motif Mutants in Cancer,3.376373e-06,5.0,3.376373e-06,-0.1844973,0.13094617
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,6.5117325e-05,22.0,6.5117325e-05,-0.004013949,-0.50856405
SMAD4 MH2 Domain Mutants in Cancer,6.428959e-07,4.0,6.428959e-07,-0.19248788,0.17054743
SRP-dependent cotranslational protein targeting to membrane,0.00043063945,49.0,0.00043063945,1.0644933,-0.9338558
STAT6-mediated induction of chemokines,4.5281823e-08,3.0,4.5281823e-08,-0.19423486,0.21486342
SUMO is conjugated to E1 (UBA2:SAE1),2.7207363e-05,4.0,2.7207363e-05,-0.11483369,0.22918618
SUMO is proteolytically processed,1.018498e-05,6.0,1.018498e-05,-0.16459413,0.100340396
"SUMO is transferred from E1 to E2 (UBE2I, UBC9)",4.5808643e-05,5.0,4.5808643e-05,-0.06045777,0.2246117
SUMOylation of DNA damage response and repair proteins,0.00021796237,51.0,0.00021796237,0.44278812,-1.4945922
SUMOylation of DNA methylation proteins,0.00038739588,9.0,0.00038739588,0.93808216,0.7960947
SUMOylation of DNA replication proteins,0.0022671157,32.0,0.0022671157,6.432946,3.8958018
SUMOylation of RNA binding proteins,0.0036969634,33.0,0.0036969634,10.612727,7.00643
SUMOylation of SUMOylation proteins,0.0012641414,28.0,0.0012641414,3.5010157,1.8643652
SUMOylation of chromatin organization proteins,0.0024246438,38.0,0.0024246438,6.893438,3.9697204
SUMOylation of immune response proteins,2.6723176e-06,11.0,2.6723176e-06,-0.1865554,-0.144419
SUMOylation of intracellular receptors,0.00014775654,21.0,0.00014775654,0.23755993,-0.28051007
SUMOylation of transcription cofactors,0.0016451632,32.0,0.0016451632,4.614832,2.5228968
SUMOylation of transcription factors,4.9026323e-05,16.0,4.9026323e-05,-0.051051736,-0.2702725
SUMOylation of ubiquitinylation proteins,3.7167778e-05,31.0,3.7167778e-05,-0.08571705,-0.9809768
Scavenging by Class A Receptors,5.797897e-08,7.0,5.797897e-08,-0.19419773,0.03235077
Scavenging by Class B Receptors,1.6549173e-09,3.0,1.6549173e-09,-0.19436239,0.21476714
Scavenging by Class F Receptors,6.1129626e-08,5.0,6.1129626e-08,-0.19418852,0.12362807
Scavenging by Class H Receptors,9.871111e-09,2.0,9.871111e-09,-0.19433835,0.26042047
Scavenging of heme from plasma,1.9406378e-10,6.0,1.9406378e-10,-0.19436665,0.07785837
SeMet incorporation into proteins,0.00022912922,8.0,0.00022912922,0.47543144,0.49237022
Selenocysteine synthesis,9.940119e-07,35.0,9.940119e-07,-0.19146149,-1.2433679
Sema3A PAK dependent Axon repulsion,2.1809956e-09,9.0,2.1809956e-09,-0.19436084,-0.05904275
Sema4D induced cell migration and growth-cone collapse,2.2162874e-07,11.0,2.2162874e-07,-0.19371936,-0.14982869
Sema4D mediated inhibition of cell attachment and migration,6.4025935e-10,5.0,6.4025935e-10,-0.19436535,0.12349454
Senescence-Associated Secretory Phenotype (SASP),1.00186235e-05,35.0,1.00186235e-05,-0.16508043,-1.2234467
Sensing of DNA Double Strand Breaks,4.1608396e-06,4.0,4.1608396e-06,-0.18220411,0.17831297
Serine biosynthesis,1.9843008e-05,6.0,1.9843008e-05,-0.13636144,0.121659644
Serotonin Neurotransmitter Release Cycle,3.4348507e-06,6.0,3.4348507e-06,-0.18432635,0.08544008
Serotonin and melatonin biosynthesis,0.0,1.0,0.0,-0.19436722,0.30603385
Severe congenital neutropenia type 4 (G6PC3),0.0,1.0,0.0,-0.19436722,0.30603385
Signal attenuation,8.186229e-07,6.0,8.186229e-07,-0.1919742,0.07966499
Signal regulatory protein family interactions,2.3895157e-09,8.0,2.3895157e-09,-0.19436024,-0.013407118
Signal transduction by L1,1.7369896e-08,13.0,1.7369896e-08,-0.19431645,-0.24154991
Signaling by BMP,3.9322917e-05,13.0,3.9322917e-05,-0.07941708,-0.15478638
Signaling by BRAF and RAF fusions,0.00014962457,36.0,0.00014962457,0.24302061,-0.96091413
Signaling by FGFR3 fusions in cancer,1.2129766e-11,9.0,1.2129766e-11,-0.19436717,-0.059047535
Signaling by FGFR3 point mutants in cancer,1.2075005e-09,11.0,1.2075005e-09,-0.19436368,-0.15031524
Signaling by Hippo,1.1075018e-07,10.0,1.1075018e-07,-0.19404347,-0.10443828
Signaling by Leptin,6.008933e-07,10.0,6.008933e-07,-0.19261067,-0.10335632
Signaling by MST1,0.0,1.0,0.0,-0.19436722,0.30603385
Signaling by RAS mutants,0.00011876117,29.0,0.00011876117,0.15279964,-0.7095963
Signaling by high-kinase activity BRAF mutants,0.00023381172,17.0,0.00023381172,0.48911947,0.09198987
Signaling by moderate kinase activity BRAF mutants,5.7251987e-07,23.0,5.7251987e-07,-0.1926936,-0.6966762
Signalling to ERK5,0.00083059643,3.0,0.00083059643,2.2336617,2.048232
Signalling to ERKs,0.0024609624,20.0,0.0024609624,6.999605,4.871323
Signalling to STAT3,0.0004847728,2.0,0.0004847728,1.2227379,1.330492
Small interfering RNA (siRNA) biogenesis,3.4261103e-09,6.0,3.4261103e-09,-0.1943572,0.07786551
Smooth Muscle Contraction,0.00011704263,17.0,0.00011704263,0.14777595,-0.16576764
"Sodium-coupled sulphate, di- and tri-carboxylate transporters",2.5241036e-07,3.0,2.5241036e-07,-0.19362937,0.21532068
Sodium/Calcium exchangers,1.0339144e-05,5.0,1.0339144e-05,-0.16414347,0.14631589
Sodium/Proton exchangers,1.0609178e-05,9.0,1.0609178e-05,-0.1633541,-0.03562874
Sperm Motility And Taxes,3.664651e-08,2.0,3.664651e-08,-0.19426009,0.2604796
Sperm:Oocyte Membrane Binding,1.0020914e-07,2.0,1.0020914e-07,-0.19407427,0.26061988
Sphingolipid de novo biosynthesis,0.00030235594,20.0,0.00030235594,0.6894904,0.106389694
Stimulation of the cell death response by PAK-2p34,4.1093433e-08,3.0,4.1093433e-08,-0.1942471,0.2148542
Striated Muscle Contraction,4.628982e-06,18.0,4.628982e-06,-0.18083562,-0.4595461
Sulfide oxidation to sulfate,2.9841716e-05,2.0,2.9841716e-05,-0.10713287,0.32627165
Surfactant metabolism,1.9454175e-05,9.0,1.9454175e-05,-0.13749808,-0.016104192
Synaptic adhesion-like molecules,5.817048e-06,12.0,5.817048e-06,-0.17736262,-0.18311247
Syndecan interactions,0.0005416748,9.0,0.0005416748,1.3890758,1.136652
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE),7.822716e-10,2.0,7.822716e-10,-0.19436492,0.2604004
Synthesis of 12-eicosatetraenoic acid derivatives,5.694743e-07,3.0,5.694743e-07,-0.19270252,0.21602057
Synthesis of 15-eicosatetraenoic acid derivatives,6.015902e-10,2.0,6.015902e-10,-0.19436546,0.2604
Synthesis of 5-eicosatetraenoic acids,2.513511e-07,4.0,2.513511e-07,-0.19363247,0.16968311
Synthesis of BMP,0.0,1.0,0.0,-0.19436722,0.30603385
Synthesis of CL,7.2423196e-09,2.0,7.2423196e-09,-0.19434606,0.26041466
Synthesis of Hepoxilins (HX) and Trioxilins (TrX),6.2660945e-08,2.0,6.2660945e-08,-0.19418405,0.260537
"Synthesis of IP2, IP, and Ins in the cytosol",1.883541e-05,9.0,1.883541e-05,-0.13930689,-0.017470052
Synthesis of IP3 and IP4 in the cytosol,7.171875e-08,15.0,7.171875e-08,-0.19415757,-0.3327003
Synthesis of IPs in the ER lumen,0.0,1.0,0.0,-0.19436722,0.30603385
Synthesis of IPs in the nucleus,1.9555163e-08,3.0,1.9555163e-08,-0.19431005,0.21480666
Synthesis of Ketone Bodies,4.514787e-09,4.0,4.514787e-09,-0.19435401,0.16913827
Synthesis of Leukotrienes (LT) and Eoxins (EX),3.4804375e-06,5.0,3.4804375e-06,-0.18419307,0.13117589
Synthesis of Lipoxins (LX),1.0989139e-06,3.0,1.0989139e-06,-0.19115482,0.21718925
Synthesis of PA,2.0881891e-06,15.0,2.0881891e-06,-0.18826294,-0.3282491
Synthesis of PC,1.361455e-07,16.0,1.361455e-07,-0.19396923,-0.37819326
Synthesis of PE,1.949729e-05,9.0,1.949729e-05,-0.13737206,-0.016009018
Synthesis of PG,6.108904e-07,7.0,6.108904e-07,-0.19258144,0.033571273
Synthesis of PI,5.468962e-08,3.0,5.468962e-08,-0.19420736,0.21488419
Synthesis of PIPs at the ER membrane,8.431502e-06,6.0,8.431502e-06,-0.16971995,0.09646975
Synthesis of PIPs at the Golgi membrane,1.7065779e-05,12.0,1.7065779e-05,-0.14447993,-0.15828188
Synthesis of PIPs at the early endosome membrane,1.9848167e-05,14.0,1.9848167e-05,-0.13634636,-0.24341033
Synthesis of PIPs at the late endosome membrane,1.4406827e-05,9.0,1.4406827e-05,-0.15225267,-0.027245767
Synthesis of PIPs at the plasma membrane,8.341226e-05,39.0,8.341226e-05,0.049466457,-1.2439775
Synthesis of PIPs in the nucleus,2.8884024e-08,4.0,2.8884024e-08,-0.19428279,0.16919206
Synthesis of PS,0.0,1.0,0.0,-0.19436722,0.30603385
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),1.13304836e-07,5.0,1.13304836e-07,-0.194036,0.123743236
Synthesis of active ubiquitin: roles of E1 and E2 enzymes,1.3230428e-08,22.0,1.3230428e-08,-0.19432855,-0.6522756
Synthesis of bile acids and bile salts,3.3007777e-06,7.0,3.3007777e-06,-0.18471828,0.039508954
Synthesis of diphthamide-EEF2,2.4675532e-07,7.0,2.4675532e-07,-0.1936459,0.032767475
Synthesis of dolichyl-phosphate mannose,2.2053337e-11,2.0,2.2053337e-11,-0.19436716,0.26039875
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET),0.0,1.0,0.0,-0.19436722,0.30603385
Synthesis of glycosylphosphatidylinositol (GPI),6.291938e-07,12.0,6.291938e-07,-0.19252793,-0.1945642
Synthesis of pyrophosphates in the cytosol,5.7570646e-06,2.0,5.7570646e-06,-0.17753796,0.27310687
Synthesis of very long-chain fatty acyl-CoAs,8.9841315e-06,13.0,8.9841315e-06,-0.16810448,-0.22175656
Synthesis of wybutosine at G37 of tRNA(Phe),1.612967e-07,2.0,1.612967e-07,-0.19389573,0.26075473
"Synthesis, secretion, and deacylation of Ghrelin",9.095872e-06,6.0,9.095872e-06,-0.16777785,0.09793628
"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",1.020127e-06,7.0,1.020127e-06,-0.19138515,0.03447462
"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",1.917532e-09,7.0,1.917532e-09,-0.19436161,0.032227024
T41 mutants of beta-catenin aren't phosphorylated,0.00020782171,11.0,0.00020782171,0.41314453,0.30843025
TAK1 activates NFkB by phosphorylation and activation of IKKs complex,2.3987375e-06,17.0,2.3987375e-06,-0.18735515,-0.41883394
"TALDO1 deficiency: failed conversion of  Fru(6)P, E4P to SH7P, GA3P",0.0,1.0,0.0,-0.19436722,0.30603385
"TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P",0.0,1.0,0.0,-0.19436722,0.30603385
TBC/RABGAPs,2.1121313e-07,29.0,2.1121313e-07,-0.19374979,-0.9712848
TCF7L2 mutants don't bind CTBP,3.2237396e-10,3.0,3.2237396e-10,-0.19436629,0.21476421
"TET1,2,3 and TDG demethylate DNA",5.5223277e-06,3.0,5.5223277e-06,-0.17822416,0.22695355
TFAP2 (AP-2) family regulates transcription of cell cycle factors,1.4381918e-07,4.0,1.4381918e-07,-0.19394681,0.16944575
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,2.133973e-08,6.0,2.133973e-08,-0.19430484,0.07790506
TFAP2 (AP-2) family regulates transcription of other transcription factors,0.0,1.0,0.0,-0.19436722,0.30603385
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation,3.858345e-08,3.0,3.858345e-08,-0.19425443,0.21484868
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),5.409082e-07,11.0,5.409082e-07,-0.19278601,-0.1491239
TGFBR1 KD Mutants in Cancer,3.2054086e-07,5.0,3.2054086e-07,-0.1934302,0.1242007
TGFBR1 LBD Mutants in Cancer,4.9372764e-05,3.0,4.9372764e-05,-0.05003901,0.32374954
TGFBR2 Kinase Domain Mutants in Cancer,4.964144e-09,3.0,4.964144e-09,-0.19435272,0.21477443
TGFBR2 MSI Frameshift Mutants in Cancer,4.0248035e-10,2.0,4.0248035e-10,-0.19436605,0.26039955
TICAM1 deficiency - HSE,0.0,1.0,0.0,-0.19436722,0.30603385
"TICAM1, RIP1-mediated IKK complex recruitment ",8.143852e-06,13.0,8.143852e-06,-0.17056082,-0.22361143
"TICAM1,TRAF6-dependent induction of TAK1 complex",6.3294383e-06,10.0,6.3294383e-06,-0.17586479,-0.09071107
TICAM1-dependent activation of IRF3/IRF7,2.970981e-07,9.0,2.970981e-07,-0.19349873,-0.058391746
TLR3 deficiency - HSE,0.0,1.0,0.0,-0.19436722,0.30603385
TLR3-mediated TICAM1-dependent programmed cell death,2.8538323e-09,5.0,2.8538323e-09,-0.19435889,0.12349943
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,0.00028496145,8.0,0.00028496145,0.6386422,0.615615
TNFR1-induced NFkappaB signaling pathway,2.3685184e-06,12.0,2.3685184e-06,-0.18744348,-0.19072479
TNFR1-induced proapoptotic signaling,3.1248154e-10,4.0,3.1248154e-10,-0.1943663,0.16912898
TNFR1-mediated ceramide production,2.374082e-08,2.0,2.374082e-08,-0.19429782,0.26045108
TNFs bind their physiological receptors,2.5525367e-07,5.0,2.5525367e-07,-0.19362105,0.124056585
TP53 Regulates Metabolic Genes,1.5748052e-06,49.0,1.5748052e-06,-0.18976368,-1.8809782
TP53 Regulates Transcription of Cell Cycle Genes,3.8570047e-07,24.0,3.8570047e-07,-0.19323973,-0.7427238
TP53 Regulates Transcription of Cell Death Genes,7.122768e-08,31.0,7.122768e-08,-0.19415902,-1.0628642
TP53 Regulates Transcription of DNA Repair Genes,2.7652715e-07,45.0,2.7652715e-07,-0.19355886,-1.7013034
TRAF3 deficiency - HSE,1.0025744e-13,2.0,1.0025744e-13,-0.19436722,0.2603987
TRAF3-dependent IRF activation pathway,2.1132892e-06,12.0,2.1132892e-06,-0.18818958,-0.19128817
TRAF6 mediated IRF7 activation,2.0511925e-05,13.0,2.0511925e-05,-0.13440603,-0.19630998
TRAF6 mediated NF-kB activation,2.9889672e-05,14.0,2.9889672e-05,-0.10699268,-0.2212446
TRAIL  signaling,2.685201e-06,7.0,2.685201e-06,-0.18651775,0.038150128
TRP channels,4.8440097e-07,4.0,4.8440097e-07,-0.19295119,0.17019758
TWIK related potassium channel (TREK),0.0,1.0,0.0,-0.19436722,0.30603385
TWIK-related alkaline pH activated K+ channel (TALK),0.0,1.0,0.0,-0.19436722,0.30603385
TWIK-related spinal cord K+ channel (TRESK),0.0,1.0,0.0,-0.19436722,0.30603385
TWIK-releated acid-sensitive K+ channel (TASK),0.0,1.0,0.0,-0.19436722,0.30603385
TYSND1 cleaves peroxisomal proteins,9.542059e-06,6.0,9.542059e-06,-0.16647354,0.0989212
Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK),1.8263493e-06,3.0,1.8263493e-06,-0.18902837,0.21879502
Tandem pore domain halothane-inhibited K+ channel (THIK),0.0,1.0,0.0,-0.19436722,0.30603385
Telomere C-strand (Lagging Strand) Synthesis,8.8325834e-08,17.0,8.8325834e-08,-0.19410904,-0.42393398
Telomere Extension By Telomerase,1.2356615e-09,2.0,1.2356615e-09,-0.19436361,0.2604014
Terminal pathway of complement,0.0,1.0,0.0,-0.19436722,0.30603385
Termination of O-glycan biosynthesis,3.5074214e-07,6.0,3.5074214e-07,-0.19334191,0.07863219
Termination of translesion DNA synthesis,5.3585383e-05,20.0,5.3585383e-05,-0.03772453,-0.44274944
"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",6.311384e-07,7.0,6.311384e-07,-0.19252226,0.03361596
The AIM2 inflammasome,2.0824965e-07,2.0,2.0824965e-07,-0.19375844,0.2608584
The IPAF inflammasome,8.927033e-07,3.0,8.927033e-07,-0.19175765,0.21673405
The NLRP1 inflammasome,6.644668e-07,3.0,6.644668e-07,-0.19242482,0.21623024
The NLRP3 inflammasome,1.8166375e-06,9.0,1.8166375e-06,-0.18905675,-0.0550375
The activation of arylsulfatases,1.7265488e-07,6.0,1.7265488e-07,-0.1938625,0.078239076
The fatty acid cycling model,0.0,1.0,0.0,-0.19436722,0.30603385
The proton buffering model,0.0,1.0,0.0,-0.19436722,0.30603385
The role of GTSE1 in G2/M progression after G2 checkpoint,5.2288757e-05,35.0,5.2288757e-05,-0.041514874,-1.1301392
The role of Nef in HIV-1 replication and disease pathogenesis,1.4553065e-05,22.0,1.4553065e-05,-0.15182519,-0.6201802
Threonine catabolism,1.2807009e-06,3.0,1.2807009e-06,-0.19062343,0.21759051
Thrombin signalling through proteinase activated receptors (PARs),0.00032458172,19.0,0.00032458172,0.7544616,0.20108631
Thromboxane signalling through TP receptor,4.5662405e-06,14.0,4.5662405e-06,-0.18101904,-0.27714384
Tie2 Signaling,2.4998179e-05,12.0,2.4998179e-05,-0.12129166,-0.1407718
Tight junction interactions,3.4682726e-09,10.0,3.4682726e-09,-0.19435707,-0.10467509
Tolerance by Mtb to nitric oxide produced by macrophages,0.0,1.0,0.0,-0.19436722,0.30603385
Tolerance of reactive oxygen produced by macrophages,0.0,1.0,0.0,-0.19436722,0.30603385
Toxicity of botulinum toxin type A (BoNT/A),3.7479124e-11,2.0,3.7479124e-11,-0.19436711,0.26039875
Toxicity of botulinum toxin type B (BoNT/B),1.0149337e-13,2.0,1.0149337e-13,-0.19436722,0.2603987
Toxicity of botulinum toxin type C (BoNT/C),2.5699947e-09,3.0,2.5699947e-09,-0.1943597,0.21476915
Toxicity of botulinum toxin type D (BoNT/D),9.3756e-10,4.0,9.3756e-10,-0.19436447,0.16913037
Toxicity of botulinum toxin type E (BoNT/E),4.659776e-12,2.0,4.659776e-12,-0.1943672,0.2603987
Toxicity of botulinum toxin type F (BoNT/F),1.03612965e-10,4.0,1.03612965e-10,-0.19436692,0.16912852
Toxicity of botulinum toxin type G (BoNT/G),2.179637e-12,3.0,2.179637e-12,-0.19436722,0.21476348
Toxicity of tetanus toxin (TeNT),8.993393e-15,2.0,8.993393e-15,-0.19436722,0.2603987
Trafficking and processing of endosomal TLR,2.5802791e-08,7.0,2.5802791e-08,-0.1942918,0.032279737
Trafficking of AMPA receptors,3.289013e-05,14.0,3.289013e-05,-0.09822163,-0.21462137
Trafficking of myristoylated proteins to the cilium,8.441896e-07,4.0,8.441896e-07,-0.19189945,0.17099178
Transcription of E2F targets under negative control by DREAM complex,0.000113600596,11.0,0.000113600596,0.13771406,0.10044541
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1,0.00011744356,6.0,0.00011744356,0.14894795,0.3371043
Transcriptional Regulation by E2F6,1.1533298e-07,22.0,1.1533298e-07,-0.19403008,-0.6520502
Transcriptional activation of mitochondrial biogenesis,1.2323154e-07,19.0,1.2323154e-07,-0.19400698,-0.5151273
Transcriptional regulation by small RNAs,2.0125393e-05,40.0,2.0125393e-05,-0.13553596,-1.4293128
Transcriptional regulation of white adipocyte differentiation,3.945642e-07,40.0,3.945642e-07,-0.19321382,-1.472867
Transfer of LPS from LBP carrier to CD14,0.0,1.0,0.0,-0.19436722,0.30603385
Transferrin endocytosis and recycling,0.0044011474,16.0,0.0044011474,12.671223,9.336652
Translesion Synthesis by POLH,8.11203e-06,12.0,8.11203e-06,-0.17065385,-0.1780465
Translesion synthesis by POLI,3.2958937e-06,11.0,3.2958937e-06,-0.18473256,-0.14304252
Translesion synthesis by POLK,0.00020116079,11.0,0.00020116079,0.39367315,0.29372686
Translesion synthesis by REV1,3.5139826e-06,11.0,3.5139826e-06,-0.18409503,-0.14256111
Translocation of SLC2A4 (GLUT4) to the plasma membrane,7.543668e-08,34.0,7.543668e-08,-0.1941467,-1.1997604
Translocation of ZAP-70 to Immunological synapse,2.129846e-11,3.0,2.129846e-11,-0.19436716,0.21476352
Transport and synthesis of PAPS,1.066904e-06,4.0,1.066904e-06,-0.19124842,0.1714834
Transport of Mature mRNA Derived from an Intronless Transcript,1.0143463e-05,11.0,1.0143463e-05,-0.16471548,-0.12792711
Transport of Mature mRNA derived from an Intron-Containing Transcript,0.00014908012,59.0,0.00014908012,0.24142908,-2.011725
Transport of Ribonucleoproteins into the Host Nucleus,1.2492569e-07,3.0,1.2492569e-07,-0.19400203,0.21503925
Transport of fatty acids,1.0648403e-05,3.0,1.0648403e-05,-0.16323943,0.2382689
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus,0.0,1.0,0.0,-0.19436722,0.30603385
Transport of glycerol from adipocytes to the liver by Aquaporins,0.0,1.0,0.0,-0.19436722,0.30603385
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,3.8532428e-07,2.0,3.8532428e-07,-0.19324082,0.26124924
Transport of nucleotide sugars,4.472023e-05,8.0,4.472023e-05,-0.06363946,0.08530358
Transport of organic anions,1.0292241e-05,4.0,1.0292241e-05,-0.16428058,0.19184752
Transport of the SLBP Dependant Mature mRNA,1.3673828e-06,6.0,1.3673828e-06,-0.19037004,0.08087633
Transport of the SLBP independent Mature mRNA,3.096142e-05,6.0,3.096142e-05,-0.10385971,0.14620255
Triglyceride biosynthesis,1.1505541e-05,7.0,1.1505541e-05,-0.16073382,0.05762026
Triglyceride catabolism,3.425608e-05,10.0,3.425608e-05,-0.09422863,-0.029065453
"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",2.0977595e-07,11.0,2.0977595e-07,-0.193754,-0.14985485
Truncations of AMER1 destabilize the destruction complex,1.1122147e-05,10.0,1.1122147e-05,-0.16185457,-0.08013158
Tryptophan catabolism,5.262836e-05,6.0,5.262836e-05,-0.04052214,0.19403045
Type I hemidesmosome assembly,1.3833844e-10,4.0,1.3833844e-10,-0.19436681,0.1691286
Type II Na+/Pi cotransporters,3.904431e-08,2.0,3.904431e-08,-0.19425309,0.26048484
UCH proteinases,7.191712e-05,61.0,7.191712e-05,0.015863458,-2.273326
UNC93B1 deficiency - HSE,0.0,1.0,0.0,-0.19436722,0.30603385
Ub-specific processing proteases,3.552766e-05,114.0,3.1164615e-07,-0.19345622,-4.7723165
Ubiquinol biosynthesis,6.700863e-07,5.0,6.700863e-07,-0.1924084,0.124972284
Ubiquitin-dependent degradation of Cyclin D1,5.6264435e-06,33.0,5.6264435e-06,-0.1779198,-1.1418719
"Unblocking of NMDA receptor, glutamate binding and activation",1.6077616e-08,6.0,1.6077616e-08,-0.19432022,0.07789344
Unwinding of DNA,1.277383e-06,9.0,1.277383e-06,-0.19063313,-0.056227867
Uptake and function of anthrax toxins,1.01218175e-05,7.0,1.01218175e-05,-0.16477877,0.054565802
Uptake and function of diphtheria toxin,6.53751e-08,3.0,6.53751e-08,-0.19417612,0.21490781
Urea cycle,5.0498937e-05,2.0,5.0498937e-05,-0.04674694,0.37187067
Utilization of Ketone Bodies,2.5855288e-08,3.0,2.5855288e-08,-0.19429164,0.21482058
VEGF binds to VEGFR leading to receptor dimerization,6.951122e-08,3.0,6.951122e-08,-0.19416401,0.21491694
VEGFR2 mediated cell proliferation,4.1214903e-06,12.0,4.1214903e-06,-0.18231913,-0.18685527
VEGFR2 mediated vascular permeability,4.5569763e-05,19.0,4.5569763e-05,-0.061156075,-0.41480803
VLDL assembly,0.0,1.0,0.0,-0.19436722,0.30603385
VLDL clearance,9.749597e-08,2.0,9.749597e-08,-0.19408222,0.2606139
VLDLR internalisation and degradation,7.0786194e-07,7.0,7.0786194e-07,-0.19229797,0.033785325
Variant SLC6A14 may confer susceptibility towards obesity,0.0,1.0,0.0,-0.19436722,0.30603385
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.19436722,0.30603385
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.19436722,0.30603385
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.19436722,0.30603385
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.19436722,0.30603385
Vasopressin regulates renal water homeostasis via Aquaporins,2.199461e-08,20.0,2.199461e-08,-0.19430292,-0.5609859
Vif-mediated degradation of APOBEC3G,1.2332865e-06,33.0,1.2332865e-06,-0.19076203,-1.1515694
Virus Assembly and Release,0.0,1.0,0.0,-0.19436722,0.30603385
Vitamin B1 (thiamin) metabolism,4.0211782e-07,4.0,4.0211782e-07,-0.19319172,0.17001595
Vitamin B2 (riboflavin) metabolism,2.0091684e-06,4.0,2.0091684e-06,-0.18849395,0.17356336
Vitamin C (ascorbate) metabolism,3.265877e-05,4.0,3.265877e-05,-0.09889795,0.24121967
Vitamin D (calciferol) metabolism,8.20345e-05,7.0,8.20345e-05,0.045438938,0.21330675
Vitamin E,0.0,1.0,0.0,-0.19436722,0.30603385
Vitamins,8.76755e-06,2.0,8.76755e-06,-0.1687376,0.27975228
Vitamins B6 activation to pyridoxal phosphate,8.773876e-11,2.0,8.773876e-11,-0.19436696,0.26039886
Voltage gated Potassium channels,1.8386764e-07,11.0,1.8386764e-07,-0.19382973,-0.14991203
Vpu mediated degradation of CD4,3.662467e-05,32.0,3.662467e-05,-0.08730468,-1.0278108
VxPx cargo-targeting to cilium,6.5951617e-06,16.0,6.5951617e-06,-0.17508802,-0.36393556
WNT ligand biogenesis and trafficking,1.599112e-05,7.0,1.599112e-05,-0.14762141,0.06752177
WNT ligand secretion is abrogated by the PORCN inhibitor LGK974,0.0,1.0,0.0,-0.19436722,0.30603385
WNT mediated activation of DVL,8.136509e-07,6.0,8.136509e-07,-0.19198874,0.07965401
"WNT5A-dependent internalization of FZD2, FZD5 and ROR2",2.4526637e-06,3.0,2.4526637e-06,-0.18719749,0.22017752
WNT5A-dependent internalization of FZD4,5.767675e-07,9.0,5.767675e-07,-0.1926812,-0.057774413
Wax biosynthesis,2.003478e-06,3.0,2.003478e-06,-0.18851058,0.21918598
"XAV939 inhibits tankyrase, stabilizing AXIN",6.716964e-07,2.0,6.716964e-07,-0.1924037,0.26188138
XBP1(S) activates chaperone genes,6.8618413e-09,31.0,6.8618413e-09,-0.19434716,-1.0630063
Xenobiotics,0.0,1.0,0.0,-0.19436722,0.30603385
YAP1- and WWTR1 (TAZ)-stimulated gene expression,2.6818816e-09,4.0,2.6818816e-09,-0.19435938,0.16913423
Zinc transporters,5.7041702e-06,8.0,5.7041702e-06,-0.17769259,-0.00082093256
alpha-linolenic acid (ALA) metabolism,1.0454244e-06,8.0,1.0454244e-06,-0.1913112,-0.01110471
c-src mediated regulation of Cx43 function and closure of gap junctions,1.153521e-05,3.0,1.153521e-05,-0.1606471,0.24022646
cGMP effects,3.0669364e-10,3.0,3.0669364e-10,-0.19436632,0.21476416
eNOS activation,9.51602e-06,7.0,9.51602e-06,-0.16654965,0.05322857
mRNA 3'-end processing,0.0002707462,46.0,0.0002707462,0.59708774,-1.1499006
mRNA Capping,0.00046209747,23.0,0.00046209747,1.1564525,0.32209954
mRNA Splicing - Major Pathway,0.001328444,133.0,9.988301e-06,-0.16516908,-2.7853858
mRNA Splicing - Minor Pathway,0.000107112646,38.0,0.000107112646,0.11874826,-1.1460258
mRNA decay by 3' to 5' exoribonuclease,3.1121397e-06,14.0,3.1121397e-06,-0.18526971,-0.28035367
mRNA decay by 5' to 3' exoribonuclease,2.0649777e-06,12.0,2.0649777e-06,-0.18833081,-0.19139484
mTORC1-mediated signalling,6.1965984e-05,12.0,6.1965984e-05,-0.013226061,-0.05916863
mitochondrial fatty acid beta-oxidation of saturated fatty acids,5.471294e-08,7.0,5.471294e-08,-0.19420728,0.032343566
mitochondrial fatty acid beta-oxidation of unsaturated fatty acids,1.1421768e-08,2.0,1.1421768e-08,-0.19433382,0.2604239
p130Cas linkage to MAPK signaling for integrins,1.8859621e-08,8.0,1.8859621e-08,-0.1943121,-0.0133707635
p53-Dependent G1 DNA Damage Response,1.7894179e-08,39.0,1.7894179e-08,-0.19431491,-1.4280633
p53-Independent DNA Damage Response,3.0247014e-07,32.0,3.0247014e-07,-0.19348304,-1.1079888
p75NTR negatively regulates cell cycle via SC1,1.4494403e-08,5.0,1.4494403e-08,-0.19432485,0.12352513
p75NTR recruits signalling complexes,1.2171776e-08,10.0,1.2171776e-08,-0.19433163,-0.10465586
rRNA modification in the mitochondrion,7.511008e-08,4.0,7.511008e-08,-0.19414766,0.16929409
rRNA modification in the nucleus and cytosol,6.0716834e-06,38.0,6.0716834e-06,-0.17661826,-1.3690649
snRNP Assembly,9.312454e-05,12.0,9.312454e-05,0.077857725,0.009611141
tRNA modification in the mitochondrion,3.0198995e-05,6.0,3.0198995e-05,-0.10608845,0.14451957
tRNA processing in the mitochondrion,6.1237824e-07,2.0,6.1237824e-07,-0.1925771,0.26175046
tRNA processing in the nucleus,4.44597e-05,39.0,4.44597e-05,-0.06440105,-1.3299619
via Dependence Receptors in the absence of ligand,6.238005e-14,9.0,6.238005e-14,-0.19436722,-0.05904757
